HRP20110757T1 - Inhibitori kinaze p38 bazirani na 5-članom heterociklu - Google Patents
Inhibitori kinaze p38 bazirani na 5-članom heterociklu Download PDFInfo
- Publication number
- HRP20110757T1 HRP20110757T1 HR20110757T HRP20110757T HRP20110757T1 HR P20110757 T1 HRP20110757 T1 HR P20110757T1 HR 20110757 T HR20110757 T HR 20110757T HR P20110757 T HRP20110757 T HR P20110757T HR P20110757 T1 HRP20110757 T1 HR P20110757T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- amino
- benzamide
- benzoyl
- cyclopropyl
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title claims abstract 63
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 title claims abstract 9
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 131
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract 7
- 230000001404 mediated effect Effects 0.000 claims abstract 5
- 239000000203 mixture Substances 0.000 claims abstract 5
- 208000024891 symptom Diseases 0.000 claims abstract 5
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 4
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 3
- 239000003112 inhibitor Substances 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 122
- 239000001257 hydrogen Substances 0.000 claims 122
- 125000000217 alkyl group Chemical group 0.000 claims 112
- 125000001072 heteroaryl group Chemical group 0.000 claims 95
- 150000002431 hydrogen Chemical class 0.000 claims 83
- -1 2-methylcyclohexyl Chemical group 0.000 claims 72
- 125000004404 heteroalkyl group Chemical group 0.000 claims 52
- 125000003118 aryl group Chemical group 0.000 claims 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 33
- 125000003342 alkenyl group Chemical group 0.000 claims 24
- 125000000304 alkynyl group Chemical group 0.000 claims 23
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 23
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 21
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- 125000001475 halogen functional group Chemical group 0.000 claims 17
- 125000002947 alkylene group Chemical group 0.000 claims 13
- 125000004474 heteroalkylene group Chemical group 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims 12
- 125000004450 alkenylene group Chemical group 0.000 claims 11
- 125000004419 alkynylene group Chemical group 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 11
- 229910020008 S(O) Inorganic materials 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 125000003282 alkyl amino group Chemical group 0.000 claims 8
- 125000005357 cycloalkylalkynyl group Chemical group 0.000 claims 8
- 125000004663 dialkyl amino group Chemical group 0.000 claims 8
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- CAZKPJSLYJYCFJ-UHFFFAOYSA-N 3-[5-amino-4-[3-(morpholin-4-ylmethyl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1CN1CCOCC1 CAZKPJSLYJYCFJ-UHFFFAOYSA-N 0.000 claims 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 239000000460 chlorine Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 125000002252 acyl group Chemical group 0.000 claims 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000004405 heteroalkoxy group Chemical group 0.000 claims 5
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- BPJJMPRXNWUAIA-UHFFFAOYSA-N 3-(5-amino-4-benzoylimidazol-1-yl)-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC=CC=C1 BPJJMPRXNWUAIA-UHFFFAOYSA-N 0.000 claims 4
- RGKYHHGPQQXTHO-UHFFFAOYSA-N 3-(5-amino-4-benzoylpyrazol-1-yl)-n-methoxy-4-methylbenzamide Chemical compound CONC(=O)C1=CC=C(C)C(N2C(=C(C(=O)C=3C=CC=CC=3)C=N2)N)=C1 RGKYHHGPQQXTHO-UHFFFAOYSA-N 0.000 claims 4
- ACDYVZWXLZVGKZ-UHFFFAOYSA-N 3-[5-amino-4-(3-formylbenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC(C=O)=C1 ACDYVZWXLZVGKZ-UHFFFAOYSA-N 0.000 claims 4
- DKDNHRIIFVRZJH-UHFFFAOYSA-N 3-[5-amino-4-(3-hydroxybenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC(O)=C1 DKDNHRIIFVRZJH-UHFFFAOYSA-N 0.000 claims 4
- OKCYOLQZTMDRPD-UHFFFAOYSA-N 3-[5-amino-4-(3-iodobenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC(I)=C1 OKCYOLQZTMDRPD-UHFFFAOYSA-N 0.000 claims 4
- QYVPOKVLADAONJ-UHFFFAOYSA-N 3-[5-amino-4-(3-iodobenzoyl)pyrazol-1-yl]-n-methoxy-4-methylbenzamide Chemical compound CONC(=O)C1=CC=C(C)C(N2C(=C(C(=O)C=3C=C(I)C=CC=3)C=N2)N)=C1 QYVPOKVLADAONJ-UHFFFAOYSA-N 0.000 claims 4
- PBHVNTIQHGFUCT-UHFFFAOYSA-N 3-[5-amino-4-(3-phenylmethoxybenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1OCC1=CC=CC=C1 PBHVNTIQHGFUCT-UHFFFAOYSA-N 0.000 claims 4
- IJWYKDHNLGMUKF-UHFFFAOYSA-N 3-[5-amino-4-(4-methylbenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1=CC(C)=CC=C1C(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N=C1 IJWYKDHNLGMUKF-UHFFFAOYSA-N 0.000 claims 4
- QIZLEKIZUYDILF-UHFFFAOYSA-N 3-[5-amino-4-[3-(1,3-dioxolan-2-yl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1C1OCCO1 QIZLEKIZUYDILF-UHFFFAOYSA-N 0.000 claims 4
- QBCXJPAVGCSFQD-UHFFFAOYSA-N 3-[5-amino-4-[3-(hydroxymethyl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC(CO)=C1 QBCXJPAVGCSFQD-UHFFFAOYSA-N 0.000 claims 4
- CGIARXZERAUCBG-UHFFFAOYSA-N 3-[5-amino-4-[3-[(4-methylpiperazin-1-yl)methyl]benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1CN(C)CCN1CC1=CC=CC(C(=O)C2=C(N(N=C2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 CGIARXZERAUCBG-UHFFFAOYSA-N 0.000 claims 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 4
- QBXUCRNTPWWBJY-UHFFFAOYSA-N [5-amino-1-[2-methyl-5-(1h-1,2,4-triazol-5-yl)phenyl]pyrazol-4-yl]-phenylmethanone Chemical compound CC1=CC=C(C=2NC=NN=2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC=C1 QBXUCRNTPWWBJY-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 125000004442 acylamino group Chemical group 0.000 claims 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 4
- 150000001412 amines Chemical group 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 4
- 125000004001 thioalkyl group Chemical group 0.000 claims 4
- 125000001425 triazolyl group Chemical group 0.000 claims 4
- RVFOYWCXKPKCPB-UHFFFAOYSA-N 3-(5-amino-4-benzoyl-3-methoxypyrazol-1-yl)-n-cyclopropyl-4-methylbenzamide Chemical compound COC1=NN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C(N)=C1C(=O)C1=CC=CC=C1 RVFOYWCXKPKCPB-UHFFFAOYSA-N 0.000 claims 3
- VTWKMMRTCFYHHB-UHFFFAOYSA-N 3-(5-amino-4-benzoylpyrazol-1-yl)-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1N1C(N)=C(C(=O)C=2C=CC=CC=2)C=N1 VTWKMMRTCFYHHB-UHFFFAOYSA-N 0.000 claims 3
- YKRHGHVJNYCHEN-UHFFFAOYSA-N 3-(5-amino-4-benzoylpyrazol-1-yl)-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC=C1 YKRHGHVJNYCHEN-UHFFFAOYSA-N 0.000 claims 3
- DDIILOABHXYXGH-UHFFFAOYSA-N 3-(5-amino-4-benzoylpyrazol-1-yl)-n-cyclopropyl-4-methylbenzamide;3-[5-amino-4-(3-iodobenzoyl)pyrazol-1-yl]-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1N1C(N)=C(C(=O)C=2C=C(I)C=CC=2)C=N1.CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC=C1 DDIILOABHXYXGH-UHFFFAOYSA-N 0.000 claims 3
- VGUSQKZDZHAAEE-UHFFFAOYSA-N 3-[5-amino-4-(3-cyanobenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC(C#N)=C1 VGUSQKZDZHAAEE-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 108091000080 Phosphotransferase Proteins 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000020233 phosphotransferase Human genes 0.000 claims 3
- 125000002577 pseudohalo group Chemical group 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 3
- SJSSFUMSAFMFNM-NSHDSACASA-N (2s)-5-(diaminomethylideneamino)-2-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 SJSSFUMSAFMFNM-NSHDSACASA-N 0.000 claims 2
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 2
- ZWWMSWCLDWRNLU-UHFFFAOYSA-N 3-(5-amino-4-benzoyl-3-methylsulfanylpyrazol-1-yl)-n-cyclopropyl-4-methylbenzamide Chemical compound CSC1=NN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C(N)=C1C(=O)C1=CC=CC=C1 ZWWMSWCLDWRNLU-UHFFFAOYSA-N 0.000 claims 2
- MRDFLILXEIMYNW-UHFFFAOYSA-N 3-(5-amino-4-benzoyl-3-methylsulfonylpyrazol-1-yl)-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=C(S(C)(=O)=O)C=1C(=O)C1=CC=CC=C1 MRDFLILXEIMYNW-UHFFFAOYSA-N 0.000 claims 2
- FWAMSEZFYAFSPS-UHFFFAOYSA-N 3-[5-amino-4-(2-phenylacetyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)CC1=CC=CC=C1 FWAMSEZFYAFSPS-UHFFFAOYSA-N 0.000 claims 2
- LPWHASBJQWRCFT-UHFFFAOYSA-N 3-[5-amino-4-(3-pyrimidin-5-ylbenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C(C=1)=CC=CC=1C1=CN=CN=C1 LPWHASBJQWRCFT-UHFFFAOYSA-N 0.000 claims 2
- LGTPWUQCBVABOR-UHFFFAOYSA-N 3-[5-amino-4-(4-fluorobenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=C(F)C=C1 LGTPWUQCBVABOR-UHFFFAOYSA-N 0.000 claims 2
- FBVHNJPDTLHFEQ-UHFFFAOYSA-N 3-[5-amino-4-(cyclohexanecarbonyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1CCCCC1 FBVHNJPDTLHFEQ-UHFFFAOYSA-N 0.000 claims 2
- JAYMLUJZZYSBGD-UHFFFAOYSA-N 3-[5-amino-4-(cyclohexanecarbonyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1CCCCC1 JAYMLUJZZYSBGD-UHFFFAOYSA-N 0.000 claims 2
- CUVLMQVWIMVXBC-UHFFFAOYSA-N 3-[5-amino-4-(cyclopentanecarbonyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1CCCC1 CUVLMQVWIMVXBC-UHFFFAOYSA-N 0.000 claims 2
- MEZFBVYCVSYZBY-UHFFFAOYSA-N 3-[5-amino-4-(oxane-4-carbonyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1CCOCC1 MEZFBVYCVSYZBY-UHFFFAOYSA-N 0.000 claims 2
- FIUNUUPXUJXOHT-UHFFFAOYSA-N 3-[5-amino-4-[3-(1h-1,2,4-triazol-5-yl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1C1=NN=CN1 FIUNUUPXUJXOHT-UHFFFAOYSA-N 0.000 claims 2
- GWHQURVCNJLILJ-UHFFFAOYSA-N 3-[5-amino-4-[3-(cyclopropylcarbamoyl)benzoyl]imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C(C=1)=CC=CC=1C(=O)NC1CC1 GWHQURVCNJLILJ-UHFFFAOYSA-N 0.000 claims 2
- JJGUJEGHJRHSGU-UHFFFAOYSA-N 3-[5-amino-4-[3-(ethylcarbamoyl)benzoyl]imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CCNC(=O)C1=CC=CC(C(=O)C2=C(N(C=N2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 JJGUJEGHJRHSGU-UHFFFAOYSA-N 0.000 claims 2
- YIAMQQAJAKAVCB-UHFFFAOYSA-N 3-[5-amino-4-[3-(propan-2-ylcarbamoyl)benzoyl]imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC(C)NC(=O)C1=CC=CC(C(=O)C2=C(N(C=N2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 YIAMQQAJAKAVCB-UHFFFAOYSA-N 0.000 claims 2
- XTUYGCBHIIZRNF-UHFFFAOYSA-N 3-[5-amino-4-[3-(propan-2-ylcarbamoyl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC(C)NC(=O)C1=CC=CC(C(=O)C2=C(N(N=C2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 XTUYGCBHIIZRNF-UHFFFAOYSA-N 0.000 claims 2
- WMNKBSHDXQFQMA-UHFFFAOYSA-N 3-[5-amino-4-[3-[2-(dimethylamino)ethylcarbamoyl]benzoyl]imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CN(C)CCNC(=O)C1=CC=CC(C(=O)C2=C(N(C=N2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 WMNKBSHDXQFQMA-UHFFFAOYSA-N 0.000 claims 2
- IBRNCFMZIGAEQJ-UHFFFAOYSA-N 3-[5-amino-4-benzoyl-3-(2-methoxyethoxy)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound COCCOC1=NN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C(N)=C1C(=O)C1=CC=CC=C1 IBRNCFMZIGAEQJ-UHFFFAOYSA-N 0.000 claims 2
- MMJUGAZRKMWPQW-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-(2,2-dimethylpropyl)pyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N1N=CC(C(=O)NCC(C)(C)C)=C1N MMJUGAZRKMWPQW-UHFFFAOYSA-N 0.000 claims 2
- FQZXHPIHEOQTOG-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-[(1-ethylpyrrolidin-2-yl)methyl]pyrazole-4-carboxamide Chemical compound CCN1CCCC1CNC(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N=C1 FQZXHPIHEOQTOG-UHFFFAOYSA-N 0.000 claims 2
- WRRVAIKMBNAKHW-UHFFFAOYSA-N 5-amino-n-benzyl-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]pyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)NCC1=CC=CC=C1 WRRVAIKMBNAKHW-UHFFFAOYSA-N 0.000 claims 2
- JNQRGPZAWRBTLS-UHFFFAOYSA-N 5-amino-n-cyclohexyl-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]pyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)NC1CCCCC1 JNQRGPZAWRBTLS-UHFFFAOYSA-N 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 101100096664 Drosophila melanogaster B52 gene Proteins 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 2
- 230000002491 angiogenic effect Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 239000002585 base Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 claims 2
- NDIUEJJIWYDFLI-UHFFFAOYSA-N ethyl 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-3-methylpyrazole-4-carboxylate Chemical compound NC1=C(C(=O)OCC)C(C)=NN1C1=CC(C(=O)NC2CC2)=CC=C1C NDIUEJJIWYDFLI-UHFFFAOYSA-N 0.000 claims 2
- UYOBDTBXSMYXJV-UHFFFAOYSA-N ethyl 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-3-methylsulfanylpyrazole-4-carboxylate Chemical compound N1=C(SC)C(C(=O)OCC)=C(N)N1C1=CC(C(=O)NC2CC2)=CC=C1C UYOBDTBXSMYXJV-UHFFFAOYSA-N 0.000 claims 2
- HNWJFUGNOHOOSC-UHFFFAOYSA-N ethyl 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]pyrazole-4-carboxylate Chemical compound NC1=C(C(=O)OCC)C=NN1C1=CC(C(=O)NC2CC2)=CC=C1C HNWJFUGNOHOOSC-UHFFFAOYSA-N 0.000 claims 2
- XAQUOOCUHCBPOP-UHFFFAOYSA-N ethyl 5-amino-3-[2-[(3-chlorophenyl)methylamino]-2-oxoethoxy]-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]pyrazole-4-carboxylate Chemical compound CCOC(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N=C1OCC(=O)NCC1=CC=CC(Cl)=C1 XAQUOOCUHCBPOP-UHFFFAOYSA-N 0.000 claims 2
- 238000005755 formation reaction Methods 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 229960002706 gusperimus Drugs 0.000 claims 2
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 claims 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 125000002524 organometallic group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- SOIIHESTBYNJRH-PMPSAXMXSA-N (3r,6r,8as)-6-(benzylsulfonylamino)-n-[3-(diaminomethylideneamino)propyl]-5-oxo-2,3,6,7,8,8a-hexahydro-[1,3]thiazolo[3,2-a]pyridine-3-carboxamide Chemical compound N([C@@H]1CC[C@@H]2SC[C@H](N2C1=O)C(=O)NCCCN=C(N)N)S(=O)(=O)CC1=CC=CC=C1 SOIIHESTBYNJRH-PMPSAXMXSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 claims 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- PUBQBMIAESKDQT-UHFFFAOYSA-N 2-[3-[5-amino-1-(4-fluorophenyl)pyrazole-4-carbonyl]phenyl]ethanesulfonamide Chemical compound NC1=C(C(=O)C=2C=C(CCS(N)(=O)=O)C=CC=2)C=NN1C1=CC=C(F)C=C1 PUBQBMIAESKDQT-UHFFFAOYSA-N 0.000 claims 1
- XTHHWFJMFDPPPP-UHFFFAOYSA-N 2-[3-[5-amino-1-(4-fluorophenyl)pyrazole-4-carbonyl]phenyl]ethenesulfonamide Chemical compound NC1=C(C(=O)C=2C=C(C=CS(N)(=O)=O)C=CC=2)C=NN1C1=CC=C(F)C=C1 XTHHWFJMFDPPPP-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 claims 1
- AFAKJAMMQAFYTN-UHFFFAOYSA-N 3-(5-amino-4-benzoyl-2-methylimidazol-1-yl)-n-cyclopropyl-4-methylbenzamide Chemical compound NC=1N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C(C)=NC=1C(=O)C1=CC=CC=C1 AFAKJAMMQAFYTN-UHFFFAOYSA-N 0.000 claims 1
- ZAZJVRMJQXOJRT-UHFFFAOYSA-N 3-(5-amino-4-benzoyl-2-propylimidazol-1-yl)-n-cyclopropyl-4-methylbenzamide Chemical compound NC=1N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C(CCC)=NC=1C(=O)C1=CC=CC=C1 ZAZJVRMJQXOJRT-UHFFFAOYSA-N 0.000 claims 1
- KIKWIBNANFKITK-UHFFFAOYSA-N 3-(5-amino-4-benzoyl-3-ethoxypyrazol-1-yl)-n-cyclopropyl-4-methylbenzamide Chemical compound CCOC1=NN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C(N)=C1C(=O)C1=CC=CC=C1 KIKWIBNANFKITK-UHFFFAOYSA-N 0.000 claims 1
- MNBBJXTXXTYEKS-UHFFFAOYSA-N 3-(5-amino-4-benzoyl-3-piperidin-4-yloxypyrazol-1-yl)-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(=C1C(=O)C=2C=CC=CC=2)N)N=C1OC1CCNCC1 MNBBJXTXXTYEKS-UHFFFAOYSA-N 0.000 claims 1
- DPEKNZKKZXXRHQ-UHFFFAOYSA-N 3-(5-amino-4-benzoyl-3-piperidin-4-yloxypyrazol-1-yl)-n-cyclopropyl-4-methylbenzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1=CC=C(C(=O)NC2CC2)C=C1N(C(=C1C(=O)C=2C=CC=CC=2)N)N=C1OC1CCNCC1 DPEKNZKKZXXRHQ-UHFFFAOYSA-N 0.000 claims 1
- XQTRXYGFWOXRCI-UHFFFAOYSA-N 3-[3-amino-1-(imidazole-1-carbonyl)-4-methylsulfonylcyclohexa-2,4-dien-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1C1(C(=O)N2C=NC=C2)CC=C(S(C)(=O)=O)C(N)=C1 XQTRXYGFWOXRCI-UHFFFAOYSA-N 0.000 claims 1
- QRUFGEHELUAQKY-UHFFFAOYSA-N 3-[5-amino-4-(1,3-benzodioxole-5-carbonyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1=C(N2C(=C(C(=O)C=3C=C4OCOC4=CC=3)N=C2)N)C(C)=CC=C1C(=O)NC1CC1 QRUFGEHELUAQKY-UHFFFAOYSA-N 0.000 claims 1
- BSUZPHZNPYYAGQ-UHFFFAOYSA-N 3-[5-amino-4-(1,3-benzodioxole-5-carbonyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1=C(N2C(=C(C(=O)C=3C=C4OCOC4=CC=3)C=N2)N)C(C)=CC=C1C(=O)NC1CC1 BSUZPHZNPYYAGQ-UHFFFAOYSA-N 0.000 claims 1
- SNDNUOZKFGUIAX-UHFFFAOYSA-N 3-[5-amino-4-(2-chlorobenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC=C1Cl SNDNUOZKFGUIAX-UHFFFAOYSA-N 0.000 claims 1
- BBDMGQNTMBSHPQ-UHFFFAOYSA-N 3-[5-amino-4-(2-fluorobenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC=C1F BBDMGQNTMBSHPQ-UHFFFAOYSA-N 0.000 claims 1
- HDERKBWRNZMYBW-UHFFFAOYSA-N 3-[5-amino-4-(2-methoxybenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound COC1=CC=CC=C1C(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N=C1 HDERKBWRNZMYBW-UHFFFAOYSA-N 0.000 claims 1
- XPCNBVHHQDGLKM-UHFFFAOYSA-N 3-[5-amino-4-(2-methylbenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=CC=C1C(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C=N1 XPCNBVHHQDGLKM-UHFFFAOYSA-N 0.000 claims 1
- FVBVNEOHHSOQGF-UHFFFAOYSA-N 3-[5-amino-4-(2-methylbenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=CC=C1C(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N=C1 FVBVNEOHHSOQGF-UHFFFAOYSA-N 0.000 claims 1
- PSBHDQNNTJDVJR-UHFFFAOYSA-N 3-[5-amino-4-(3,4-dichlorobenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC=C(Cl)C(Cl)=C1 PSBHDQNNTJDVJR-UHFFFAOYSA-N 0.000 claims 1
- MXLHPIUQGKLAOC-UHFFFAOYSA-N 3-[5-amino-4-(3,4-difluorobenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC=C(F)C(F)=C1 MXLHPIUQGKLAOC-UHFFFAOYSA-N 0.000 claims 1
- HDPMVQIXPBKBON-UHFFFAOYSA-N 3-[5-amino-4-(3,4-difluorobenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=C(F)C(F)=C1 HDPMVQIXPBKBON-UHFFFAOYSA-N 0.000 claims 1
- ZFYVSACDOCZPOZ-UHFFFAOYSA-N 3-[5-amino-4-(3,4-dimethoxybenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C=N1 ZFYVSACDOCZPOZ-UHFFFAOYSA-N 0.000 claims 1
- SQHAIUSAMRDZNZ-UHFFFAOYSA-N 3-[5-amino-4-(3,4-dimethoxybenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N=C1 SQHAIUSAMRDZNZ-UHFFFAOYSA-N 0.000 claims 1
- GFOLAFMQMOLCGS-UHFFFAOYSA-N 3-[5-amino-4-(3,5-dichlorobenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC(Cl)=CC(Cl)=C1 GFOLAFMQMOLCGS-UHFFFAOYSA-N 0.000 claims 1
- XTAMKIQNZVLGSF-UHFFFAOYSA-N 3-[5-amino-4-(3,5-difluorobenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC(F)=CC(F)=C1 XTAMKIQNZVLGSF-UHFFFAOYSA-N 0.000 claims 1
- JKWKJZQELQETOD-UHFFFAOYSA-N 3-[5-amino-4-(3,5-difluorobenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC(F)=CC(F)=C1 JKWKJZQELQETOD-UHFFFAOYSA-N 0.000 claims 1
- OSUZGEISJKMBQR-UHFFFAOYSA-N 3-[5-amino-4-(3-carbamoylbenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC=CC(C(N)=O)=C1 OSUZGEISJKMBQR-UHFFFAOYSA-N 0.000 claims 1
- NZXOIXMLLBUJNS-UHFFFAOYSA-N 3-[5-amino-4-(3-carbamoylbenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC(C(N)=O)=C1 NZXOIXMLLBUJNS-UHFFFAOYSA-N 0.000 claims 1
- VOAXOKDGTITUTM-UHFFFAOYSA-N 3-[5-amino-4-(3-chlorobenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC=CC(Cl)=C1 VOAXOKDGTITUTM-UHFFFAOYSA-N 0.000 claims 1
- CBZDQAKGPASDBV-UHFFFAOYSA-N 3-[5-amino-4-(3-chlorobenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC(Cl)=C1 CBZDQAKGPASDBV-UHFFFAOYSA-N 0.000 claims 1
- SMYZXGDBRUAGAU-UHFFFAOYSA-N 3-[5-amino-4-(3-cyclopropyloxybenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1OC1CC1 SMYZXGDBRUAGAU-UHFFFAOYSA-N 0.000 claims 1
- OTMBBTYQTWKZSR-UHFFFAOYSA-N 3-[5-amino-4-(3-ethenoxybenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC(OC=C)=C1 OTMBBTYQTWKZSR-UHFFFAOYSA-N 0.000 claims 1
- HLWZGSJPMBKNAF-UHFFFAOYSA-N 3-[5-amino-4-(3-ethoxybenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CCOC1=CC=CC(C(=O)C2=C(N(N=C2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 HLWZGSJPMBKNAF-UHFFFAOYSA-N 0.000 claims 1
- VGMBIWKCWYFQMA-UHFFFAOYSA-N 3-[5-amino-4-(3-fluorobenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC=CC(F)=C1 VGMBIWKCWYFQMA-UHFFFAOYSA-N 0.000 claims 1
- MDJBURFRNKRXTC-UHFFFAOYSA-N 3-[5-amino-4-(3-fluorobenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC(F)=C1 MDJBURFRNKRXTC-UHFFFAOYSA-N 0.000 claims 1
- XZYMRFDWWBDMRD-UHFFFAOYSA-N 3-[5-amino-4-(3-methoxybenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound COC1=CC=CC(C(=O)C2=C(N(C=N2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 XZYMRFDWWBDMRD-UHFFFAOYSA-N 0.000 claims 1
- KYTKOPCTWBUQAK-UHFFFAOYSA-N 3-[5-amino-4-(3-methoxybenzoyl)pyrazol-1-yl]-n,4-dimethylbenzamide Chemical compound CNC(=O)C1=CC=C(C)C(N2C(=C(C(=O)C=3C=C(OC)C=CC=3)C=N2)N)=C1 KYTKOPCTWBUQAK-UHFFFAOYSA-N 0.000 claims 1
- NMTQDBBVXVRVBR-UHFFFAOYSA-N 3-[5-amino-4-(3-methoxybenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound COC1=CC=CC(C(=O)C2=C(N(N=C2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 NMTQDBBVXVRVBR-UHFFFAOYSA-N 0.000 claims 1
- WBBNMFQHIHEKPO-UHFFFAOYSA-N 3-[5-amino-4-(3-methylbenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=CC(C(=O)C2=C(N(N=C2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 WBBNMFQHIHEKPO-UHFFFAOYSA-N 0.000 claims 1
- DXVFTBMVKRQXNK-UHFFFAOYSA-N 3-[5-amino-4-(3-methylsulfanylbenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CSC1=CC=CC(C(=O)C2=C(N(N=C2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 DXVFTBMVKRQXNK-UHFFFAOYSA-N 0.000 claims 1
- XQQURLRZMWPYON-UHFFFAOYSA-N 3-[5-amino-4-(3-phenylmethoxybenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C(C=1)=CC=CC=1OCC1=CC=CC=C1 XQQURLRZMWPYON-UHFFFAOYSA-N 0.000 claims 1
- SFQHBOLXISPDBA-UHFFFAOYSA-N 3-[5-amino-4-(3-pyrazin-2-ylbenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C(C=1)=CC=CC=1C1=CN=CC=N1 SFQHBOLXISPDBA-UHFFFAOYSA-N 0.000 claims 1
- KFEHIKXVOVHDSQ-UHFFFAOYSA-N 3-[5-amino-4-(3-pyrazin-2-ylbenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1C1=CN=CC=N1 KFEHIKXVOVHDSQ-UHFFFAOYSA-N 0.000 claims 1
- RETMUTIDBSWREN-UHFFFAOYSA-N 3-[5-amino-4-(3-pyridin-2-ylbenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1C1=CC=CC=N1 RETMUTIDBSWREN-UHFFFAOYSA-N 0.000 claims 1
- XWGSTRFFSXATEC-UHFFFAOYSA-N 3-[5-amino-4-(3-pyrimidin-2-ylbenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C(C=1)=CC=CC=1C1=NC=CC=N1 XWGSTRFFSXATEC-UHFFFAOYSA-N 0.000 claims 1
- HKFCLMICDLIMGJ-UHFFFAOYSA-N 3-[5-amino-4-(4-chlorobenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC=C(Cl)C=C1 HKFCLMICDLIMGJ-UHFFFAOYSA-N 0.000 claims 1
- NYXMCXWVOJYFJF-UHFFFAOYSA-N 3-[5-amino-4-(4-chlorobenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=C(Cl)C=C1 NYXMCXWVOJYFJF-UHFFFAOYSA-N 0.000 claims 1
- HZNJNTZARAIANJ-UHFFFAOYSA-N 3-[5-amino-4-(4-fluoro-3-methylbenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC=C(F)C(C)=C1 HZNJNTZARAIANJ-UHFFFAOYSA-N 0.000 claims 1
- UPUWULSKOMSEMQ-UHFFFAOYSA-N 3-[5-amino-4-(4-fluoro-3-methylbenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=C(F)C(C)=C1 UPUWULSKOMSEMQ-UHFFFAOYSA-N 0.000 claims 1
- UMIPFOBBFUSFHO-UHFFFAOYSA-N 3-[5-amino-4-(4-fluorobenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC=C(F)C=C1 UMIPFOBBFUSFHO-UHFFFAOYSA-N 0.000 claims 1
- ZSRVTIJZIHJWOE-UHFFFAOYSA-N 3-[5-amino-4-(4-methoxybenzoyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C=N1 ZSRVTIJZIHJWOE-UHFFFAOYSA-N 0.000 claims 1
- QMTXKMXNPWHWNQ-UHFFFAOYSA-N 3-[5-amino-4-(4-methoxybenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N=C1 QMTXKMXNPWHWNQ-UHFFFAOYSA-N 0.000 claims 1
- MQOFLUXAFQFEJW-UHFFFAOYSA-N 3-[5-amino-4-(4-methylsulfanylbenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1=CC(SC)=CC=C1C(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N=C1 MQOFLUXAFQFEJW-UHFFFAOYSA-N 0.000 claims 1
- XTYQKGYMCJFGOF-UHFFFAOYSA-N 3-[5-amino-4-(5-chlorothiophene-2-carbonyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC=C(Cl)S1 XTYQKGYMCJFGOF-UHFFFAOYSA-N 0.000 claims 1
- VJWWFRKWQCGWKN-UHFFFAOYSA-N 3-[5-amino-4-(cyclopentanecarbonyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1CCCC1 VJWWFRKWQCGWKN-UHFFFAOYSA-N 0.000 claims 1
- BTZHHISSQCYPQN-UHFFFAOYSA-N 3-[5-amino-4-(piperidine-1-carbonyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)N1CCCCC1 BTZHHISSQCYPQN-UHFFFAOYSA-N 0.000 claims 1
- QOHZEPHIRKPEPH-UHFFFAOYSA-N 3-[5-amino-4-(pyridine-2-carbonyl)imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC=CC=N1 QOHZEPHIRKPEPH-UHFFFAOYSA-N 0.000 claims 1
- SDMIRTQDZFHAOX-UHFFFAOYSA-N 3-[5-amino-4-(pyridine-2-carbonyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC=N1 SDMIRTQDZFHAOX-UHFFFAOYSA-N 0.000 claims 1
- ZZNYXQJNVFQHTQ-UHFFFAOYSA-N 3-[5-amino-4-[3-(1,3,4-oxadiazol-2-yl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1C1=NN=CO1 ZZNYXQJNVFQHTQ-UHFFFAOYSA-N 0.000 claims 1
- BYYCNVVPNSHOFO-UHFFFAOYSA-N 3-[5-amino-4-[3-(1,3,4-oxadiazol-2-ylmethoxy)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1OCC1=NN=CO1 BYYCNVVPNSHOFO-UHFFFAOYSA-N 0.000 claims 1
- MFHUKYIZESKECO-UHFFFAOYSA-N 3-[5-amino-4-[3-(2,3-dihydroxypropoxy)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC(OCC(O)CO)=C1 MFHUKYIZESKECO-UHFFFAOYSA-N 0.000 claims 1
- NVSDSDJBNGMPFI-UHFFFAOYSA-N 3-[5-amino-4-[3-(2-amino-2-oxoethoxy)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC(OCC(N)=O)=C1 NVSDSDJBNGMPFI-UHFFFAOYSA-N 0.000 claims 1
- JZZJLWXEAXTBMS-UHFFFAOYSA-N 3-[5-amino-4-[3-(2-morpholin-4-yl-2-oxoethoxy)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1OCC(=O)N1CCOCC1 JZZJLWXEAXTBMS-UHFFFAOYSA-N 0.000 claims 1
- AHZPFPLQACREBZ-UHFFFAOYSA-N 3-[5-amino-4-[3-(2-morpholin-4-ylethoxy)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1OCCN1CCOCC1 AHZPFPLQACREBZ-UHFFFAOYSA-N 0.000 claims 1
- SZGBTXZOHAOTDC-UHFFFAOYSA-N 3-[5-amino-4-[3-(2-oxo-2-piperazin-1-ylethoxy)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1OCC(=O)N1CCNCC1 SZGBTXZOHAOTDC-UHFFFAOYSA-N 0.000 claims 1
- KTQPECIQEHQUBN-UHFFFAOYSA-N 3-[5-amino-4-[3-(cyclopentylcarbamoyl)benzoyl]imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C(C=1)=CC=CC=1C(=O)NC1CCCC1 KTQPECIQEHQUBN-UHFFFAOYSA-N 0.000 claims 1
- DPCKPLDRWBJWQT-UHFFFAOYSA-N 3-[5-amino-4-[3-(cyclopentylcarbamoyl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1C(=O)NC1CCCC1 DPCKPLDRWBJWQT-UHFFFAOYSA-N 0.000 claims 1
- LWSRVULNCATYJI-UHFFFAOYSA-N 3-[5-amino-4-[3-(cyclopropylcarbamoyl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1C(=O)NC1CC1 LWSRVULNCATYJI-UHFFFAOYSA-N 0.000 claims 1
- GIHHUEQCXCRWJE-UHFFFAOYSA-N 3-[5-amino-4-[3-(cyclopropylmethylcarbamoyl)benzoyl]imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C(C=1)=CC=CC=1C(=O)NCC1CC1 GIHHUEQCXCRWJE-UHFFFAOYSA-N 0.000 claims 1
- GTDZZPVASBZOKT-UHFFFAOYSA-N 3-[5-amino-4-[3-(cyclopropylmethylcarbamoyl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1C(=O)NCC1CC1 GTDZZPVASBZOKT-UHFFFAOYSA-N 0.000 claims 1
- WFODLPTZTGBFCK-UHFFFAOYSA-N 3-[5-amino-4-[3-(dimethylcarbamoyl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(C(=O)C2=C(N(N=C2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 WFODLPTZTGBFCK-UHFFFAOYSA-N 0.000 claims 1
- URMDGTARRHYTAF-UHFFFAOYSA-N 3-[5-amino-4-[3-(ethylcarbamoyl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CCNC(=O)C1=CC=CC(C(=O)C2=C(N(N=C2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 URMDGTARRHYTAF-UHFFFAOYSA-N 0.000 claims 1
- XLLYYZFEKYFKCJ-UHFFFAOYSA-N 3-[5-amino-4-[3-(hydrazinecarbonyl)benzoyl]imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC=CC(C(=O)NN)=C1 XLLYYZFEKYFKCJ-UHFFFAOYSA-N 0.000 claims 1
- YHMILFSWUBXEDD-UHFFFAOYSA-N 3-[5-amino-4-[3-(hydrazinecarbonyl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC(C(=O)NN)=C1 YHMILFSWUBXEDD-UHFFFAOYSA-N 0.000 claims 1
- IWNKJMJSWQTJTK-UHFFFAOYSA-N 3-[5-amino-4-[3-(methylcarbamoyl)benzoyl]imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C(=O)C2=C(N(C=N2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 IWNKJMJSWQTJTK-UHFFFAOYSA-N 0.000 claims 1
- FFCKFEWFUGEEHI-UHFFFAOYSA-N 3-[5-amino-4-[3-(methylcarbamoyl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C(=O)C2=C(N(N=C2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 FFCKFEWFUGEEHI-UHFFFAOYSA-N 0.000 claims 1
- BJSOXWXTCNQKHK-UHFFFAOYSA-N 3-[5-amino-4-[3-(morpholine-4-carbonyl)benzoyl]imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C(C=1)=CC=CC=1C(=O)N1CCOCC1 BJSOXWXTCNQKHK-UHFFFAOYSA-N 0.000 claims 1
- VYWHELGLXHTRRO-UHFFFAOYSA-N 3-[5-amino-4-[3-(piperazine-1-carbonyl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1C(=O)N1CCNCC1 VYWHELGLXHTRRO-UHFFFAOYSA-N 0.000 claims 1
- YCDAFRAMDAOVEW-UHFFFAOYSA-N 3-[5-amino-4-[3-(pyrrolidine-1-carbonyl)benzoyl]imidazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C(C=1)=CC=CC=1C(=O)N1CCCC1 YCDAFRAMDAOVEW-UHFFFAOYSA-N 0.000 claims 1
- DUIZSOYAUAPVQB-UHFFFAOYSA-N 3-[5-amino-4-[3-[(2-morpholin-4-ylethylamino)methyl]benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1CNCCN1CCOCC1 DUIZSOYAUAPVQB-UHFFFAOYSA-N 0.000 claims 1
- ROVPYNZGPGBKPE-UHFFFAOYSA-N 3-[5-amino-4-[3-[(3-morpholin-4-ylpropylamino)methyl]benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1CNCCCN1CCOCC1 ROVPYNZGPGBKPE-UHFFFAOYSA-N 0.000 claims 1
- GOOXRKXIMWNBCQ-UHFFFAOYSA-N 3-[5-amino-4-[3-[2-(1h-benzimidazol-2-ylmethylamino)-2-oxoethoxy]benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1=C(N2C(=C(C(=O)C=3C=C(OCC(=O)NCC=4NC5=CC=CC=C5N=4)C=CC=3)C=N2)N)C(C)=CC=C1C(=O)NC1CC1 GOOXRKXIMWNBCQ-UHFFFAOYSA-N 0.000 claims 1
- DYWDDDAAALMHQI-UHFFFAOYSA-N 3-[5-amino-4-[3-[2-(3,5-dimethylpiperazin-1-yl)-2-oxoethoxy]benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1C(C)NC(C)CN1C(=O)COC1=CC=CC(C(=O)C2=C(N(N=C2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 DYWDDDAAALMHQI-UHFFFAOYSA-N 0.000 claims 1
- RSDIQTPRWZRXFT-UHFFFAOYSA-N 3-[5-amino-4-[3-[2-(3-aminopyrrolidin-1-yl)-2-oxoethoxy]benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1OCC(=O)N1CCC(N)C1 RSDIQTPRWZRXFT-UHFFFAOYSA-N 0.000 claims 1
- CTZPDPTZEHWTFT-UHFFFAOYSA-N 3-[5-amino-4-[3-[2-(4-chlorophenoxy)ethoxy]benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1OCCOC1=CC=C(Cl)C=C1 CTZPDPTZEHWTFT-UHFFFAOYSA-N 0.000 claims 1
- TZJHPUMDMRWORP-UHFFFAOYSA-N 3-[5-amino-4-[3-[2-(4-methylpiperazin-1-yl)ethoxy]benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1CN(C)CCN1CCOC1=CC=CC(C(=O)C2=C(N(N=C2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 TZJHPUMDMRWORP-UHFFFAOYSA-N 0.000 claims 1
- CNBLHETWXFUGBM-UHFFFAOYSA-N 3-[5-amino-4-[3-[2-(dimethylamino)ethoxy]benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CN(C)CCOC1=CC=CC(C(=O)C2=C(N(N=C2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 CNBLHETWXFUGBM-UHFFFAOYSA-N 0.000 claims 1
- IBPSLBAAKMCRHL-UHFFFAOYSA-N 3-[5-amino-4-[3-[2-[2-(5-chloro-2-hydroxyphenyl)ethylamino]-2-oxoethoxy]benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1OCC(=O)NCCC1=CC(Cl)=CC=C1O IBPSLBAAKMCRHL-UHFFFAOYSA-N 0.000 claims 1
- FMZGCTIWLXIUQL-UHFFFAOYSA-N 3-[5-amino-4-[3-[2-[bis(2-hydroxyethyl)amino]ethoxy]benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC(OCCN(CCO)CCO)=C1 FMZGCTIWLXIUQL-UHFFFAOYSA-N 0.000 claims 1
- IFXZWOGEOSTNCW-UHFFFAOYSA-N 3-[5-amino-4-[3-[[(3-chlorophenyl)methylamino]methyl]benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1CNCC1=CC=CC(Cl)=C1 IFXZWOGEOSTNCW-UHFFFAOYSA-N 0.000 claims 1
- RXPMDLIAHNWJJT-UHFFFAOYSA-N 3-[5-amino-4-[3-[[2-(3-chlorophenyl)ethylamino]methyl]benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1CNCCC1=CC=CC(Cl)=C1 RXPMDLIAHNWJJT-UHFFFAOYSA-N 0.000 claims 1
- MPJRRONNCAIPHI-UHFFFAOYSA-N 3-[5-amino-4-[3-[[4-(3-chlorophenyl)piperazin-1-yl]methyl]benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=1)=CC=CC=1CN(CC1)CCN1C1=CC=CC(Cl)=C1 MPJRRONNCAIPHI-UHFFFAOYSA-N 0.000 claims 1
- KOCORNWMDVQDSR-UHFFFAOYSA-N 3-[5-amino-4-[4-(cyclopropylcarbamoyl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C(C=C1)=CC=C1C(=O)NC1CC1 KOCORNWMDVQDSR-UHFFFAOYSA-N 0.000 claims 1
- JXJYQFYCGIGSAP-UHFFFAOYSA-N 3-[5-amino-4-[4-(methylcarbamoyl)benzoyl]pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1C(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N=C1 JXJYQFYCGIGSAP-UHFFFAOYSA-N 0.000 claims 1
- CLLNNUXIRVVIGL-UHFFFAOYSA-N 3-[5-amino-4-benzoyl-3-(2-phenylmethoxyethoxy)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(=C1C(=O)C=2C=CC=CC=2)N)N=C1OCCOCC1=CC=CC=C1 CLLNNUXIRVVIGL-UHFFFAOYSA-N 0.000 claims 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000006495 3-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- GMWIFQKRSOVLLY-UHFFFAOYSA-N 5-amino-1-[3-(cyclopropylcarbamoyl)-1-methylcyclohexa-2,4-dien-1-yl]-3-methylsulfonylpyrazole-4-carboxamide Chemical compound C=1C(C)(N2C(=C(C(N)=O)C(=N2)S(C)(=O)=O)N)CC=CC=1C(=O)NC1CC1 GMWIFQKRSOVLLY-UHFFFAOYSA-N 0.000 claims 1
- WZHKUUKNBFRHCJ-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-3-methylsulfanylpyrazole-4-carboxamide Chemical compound NC1=C(C(N)=O)C(SC)=NN1C1=CC(C(=O)NC2CC2)=CC=C1C WZHKUUKNBFRHCJ-UHFFFAOYSA-N 0.000 claims 1
- GIZZQOYCBNYPPO-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-3-methylsulfonylpyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N1N=C(S(C)(=O)=O)C(C(N)=O)=C1N GIZZQOYCBNYPPO-UHFFFAOYSA-N 0.000 claims 1
- UVOJFDDTPRNBAQ-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-(1-phenylethyl)pyrazole-4-carboxamide Chemical compound C=1C=CC=CC=1C(C)NC(=O)C(=C1N)C=NN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 UVOJFDDTPRNBAQ-UHFFFAOYSA-N 0.000 claims 1
- ZRJWETXXZIYGEX-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-(2,3-dihydro-1h-inden-1-yl)pyrazole-4-carboxamide Chemical compound C1=C(N2C(=C(C(=O)NC3C4=CC=CC=C4CC3)C=N2)N)C(C)=CC=C1C(=O)NC1CC1 ZRJWETXXZIYGEX-UHFFFAOYSA-N 0.000 claims 1
- WEAZEYUNGJJQAE-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-(2-methylcyclohexyl)pyrazole-4-carboxamide Chemical compound CC1CCCCC1NC(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N=C1 WEAZEYUNGJJQAE-UHFFFAOYSA-N 0.000 claims 1
- IEBFZPFGPKHGNJ-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-(2-morpholin-4-ylethyl)pyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)NCCN1CCOCC1 IEBFZPFGPKHGNJ-UHFFFAOYSA-N 0.000 claims 1
- YNNQDXMENYDQLN-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-(2-pyrrolidin-1-ylethyl)pyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)NCCN1CCCC1 YNNQDXMENYDQLN-UHFFFAOYSA-N 0.000 claims 1
- WZKBAIQGYRAHKE-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-(4-methylcyclohexyl)pyrazole-4-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N=C1 WZKBAIQGYRAHKE-UHFFFAOYSA-N 0.000 claims 1
- HRKJYWZVISHPFE-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-(pyridin-2-ylmethyl)pyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)NCC1=CC=CC=N1 HRKJYWZVISHPFE-UHFFFAOYSA-N 0.000 claims 1
- GUWHVUDVNMLCFC-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-[(2,4-dichlorophenyl)methyl]pyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)NCC1=CC=C(Cl)C=C1Cl GUWHVUDVNMLCFC-UHFFFAOYSA-N 0.000 claims 1
- UAAWPDRJRQISRT-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-[(2-methylphenyl)methyl]pyrazole-4-carboxamide Chemical compound CC1=CC=CC=C1CNC(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N=C1 UAAWPDRJRQISRT-UHFFFAOYSA-N 0.000 claims 1
- ZUYSJNWSYHONTI-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-[(3,4-dichlorophenyl)methyl]pyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)NCC1=CC=C(Cl)C(Cl)=C1 ZUYSJNWSYHONTI-UHFFFAOYSA-N 0.000 claims 1
- OIJPWNXFILFVLG-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-[(3-methoxyphenyl)methyl]pyrazole-4-carboxamide Chemical compound COC1=CC=CC(CNC(=O)C2=C(N(N=C2)C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N)=C1 OIJPWNXFILFVLG-UHFFFAOYSA-N 0.000 claims 1
- RFXQTDATIWWAFT-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-[(4-fluorophenyl)methyl]pyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)NCC1=CC=C(F)C=C1 RFXQTDATIWWAFT-UHFFFAOYSA-N 0.000 claims 1
- JMKGIFRMKXGUON-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-[(4-methoxyphenyl)methyl]pyrazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=C(N)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)N=C1 JMKGIFRMKXGUON-UHFFFAOYSA-N 0.000 claims 1
- SFWKDXSIHFVYDZ-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-[[3-(trifluoromethyl)phenyl]methyl]pyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)NCC1=CC=CC(C(F)(F)F)=C1 SFWKDXSIHFVYDZ-UHFFFAOYSA-N 0.000 claims 1
- LYCMDHZHFYQIAM-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-pentan-3-ylpyrazole-4-carboxamide Chemical compound NC1=C(C(=O)NC(CC)CC)C=NN1C1=CC(C(=O)NC2CC2)=CC=C1C LYCMDHZHFYQIAM-UHFFFAOYSA-N 0.000 claims 1
- LWBQILFACCYKDY-UHFFFAOYSA-N 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-phenylpyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)NC1=CC=CC=C1 LWBQILFACCYKDY-UHFFFAOYSA-N 0.000 claims 1
- GGDRLUXXWYQHRV-UHFFFAOYSA-N 5-amino-n-(1-cyclohexylethyl)-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]pyrazole-4-carboxamide Chemical compound C1CCCCC1C(C)NC(=O)C(=C1N)C=NN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 GGDRLUXXWYQHRV-UHFFFAOYSA-N 0.000 claims 1
- BLTIPOAYKWUMEJ-UHFFFAOYSA-N 5-amino-n-(4-tert-butylcyclohexyl)-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]pyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)NC1CCC(C(C)(C)C)CC1 BLTIPOAYKWUMEJ-UHFFFAOYSA-N 0.000 claims 1
- MLBJXVQODRHDJN-UHFFFAOYSA-N 5-amino-n-(cyclohexylmethyl)-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]pyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)NCC1CCCCC1 MLBJXVQODRHDJN-UHFFFAOYSA-N 0.000 claims 1
- COVNAIQDIRCDFC-UHFFFAOYSA-N 5-amino-n-[(3-chlorophenyl)methyl]-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]pyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)NCC1=CC=CC(Cl)=C1 COVNAIQDIRCDFC-UHFFFAOYSA-N 0.000 claims 1
- ROSIUOKVQFBNRG-UHFFFAOYSA-N 5-amino-n-cyclohexyl-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-n-methylpyrazole-4-carboxamide Chemical compound C1=NN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C(N)=C1C(=O)N(C)C1CCCCC1 ROSIUOKVQFBNRG-UHFFFAOYSA-N 0.000 claims 1
- SQIGUAUKEZDZMW-UHFFFAOYSA-N 5-amino-n-cyclopentyl-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]pyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)NC1CCCC1 SQIGUAUKEZDZMW-UHFFFAOYSA-N 0.000 claims 1
- AMUNEMIHEULGKP-UHFFFAOYSA-N 5-amino-n-cyclopropyl-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]pyrazole-4-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)NC1CC1 AMUNEMIHEULGKP-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000004429 Bacillary Dysentery Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010063094 Cerebral malaria Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000037487 Endotoxemia Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 1
- 206010040550 Shigella infections Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 206010043781 Thyroiditis chronic Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010048873 Traumatic arthritis Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- PGYCOFUREUQZPC-UHFFFAOYSA-N [3-(2-aminoethyl)phenyl]-[5-amino-1-(4-fluorophenyl)pyrazol-4-yl]methanone Chemical compound NCCC1=CC=CC(C(=O)C2=C(N(N=C2)C=2C=CC(F)=CC=2)N)=C1 PGYCOFUREUQZPC-UHFFFAOYSA-N 0.000 claims 1
- LJHVYEURSIWGNU-UHFFFAOYSA-N [5-amino-1-(2,4-difluorophenyl)pyrazol-4-yl]-[3-(2-hydroxyethylsulfonyl)phenyl]methanone Chemical compound NC1=C(C(=O)C=2C=C(C=CC=2)S(=O)(=O)CCO)C=NN1C1=CC=C(F)C=C1F LJHVYEURSIWGNU-UHFFFAOYSA-N 0.000 claims 1
- SQCPBLIPSNRAEA-UHFFFAOYSA-N [5-amino-1-(2,4-difluorophenyl)pyrazol-4-yl]-[3-(3-morpholin-4-ylpropyl)phenyl]methanone Chemical compound NC1=C(C(=O)C=2C=C(CCCN3CCOCC3)C=CC=2)C=NN1C1=CC=C(F)C=C1F SQCPBLIPSNRAEA-UHFFFAOYSA-N 0.000 claims 1
- FWYUZBFZDMKZKU-UHFFFAOYSA-N [5-amino-1-(2-methylphenyl)pyrazol-4-yl]-[3-(1-oxidopyridin-1-ium-3-yl)phenyl]methanone Chemical compound CC1=CC=CC=C1N1C(N)=C(C(=O)C=2C=C(C=CC=2)C=2C=[N+]([O-])C=CC=2)C=N1 FWYUZBFZDMKZKU-UHFFFAOYSA-N 0.000 claims 1
- FNLHEQLQLSXRBY-UHFFFAOYSA-N [5-amino-1-(4-fluorophenyl)pyrazol-4-yl]-(3-aminophenyl)methanone Chemical compound NC1=C(C(=O)C=2C=C(N)C=CC=2)C=NN1C1=CC=C(F)C=C1 FNLHEQLQLSXRBY-UHFFFAOYSA-N 0.000 claims 1
- MDPZNDLAGKIDFD-UHFFFAOYSA-N [5-amino-1-(4-fluorophenyl)pyrazol-4-yl]-(3-pyridin-3-ylphenyl)methanone Chemical compound NC1=C(C(=O)C=2C=C(C=CC=2)C=2C=NC=CC=2)C=NN1C1=CC=C(F)C=C1 MDPZNDLAGKIDFD-UHFFFAOYSA-N 0.000 claims 1
- NETMPCVQLSKQCS-UHFFFAOYSA-N [5-amino-1-(4-fluorophenyl)pyrazol-4-yl]-[3-(1,2-dihydroxyethyl)phenyl]methanone Chemical compound NC1=C(C(=O)C=2C=C(C=CC=2)C(O)CO)C=NN1C1=CC=C(F)C=C1 NETMPCVQLSKQCS-UHFFFAOYSA-N 0.000 claims 1
- IJDQETGUEUJVTB-UHFFFAOYSA-N [5-amino-1-(4-fluorophenyl)pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone Chemical compound NC1=C(C(=O)C=2C=C(OCC(O)CO)C=CC=2)C=NN1C1=CC=C(F)C=C1 IJDQETGUEUJVTB-UHFFFAOYSA-N 0.000 claims 1
- FAOCNBXKNCERRY-UHFFFAOYSA-N [5-amino-1-(4-fluorophenyl)pyrazol-4-yl]-[3-(2-methylsulfonylethyl)phenyl]methanone Chemical compound CS(=O)(=O)CCC1=CC=CC(C(=O)C2=C(N(N=C2)C=2C=CC(F)=CC=2)N)=C1 FAOCNBXKNCERRY-UHFFFAOYSA-N 0.000 claims 1
- AZPXSGWGNRAGOU-UHFFFAOYSA-N [5-amino-1-(4-fluorophenyl)pyrazol-4-yl]-[3-(2-morpholin-4-ylethoxy)phenyl]methanone Chemical compound NC1=C(C(=O)C=2C=C(OCCN3CCOCC3)C=CC=2)C=NN1C1=CC=C(F)C=C1 AZPXSGWGNRAGOU-UHFFFAOYSA-N 0.000 claims 1
- VYZNEDVUQBPGQA-UHFFFAOYSA-N [5-amino-1-(4-fluorophenyl)pyrazol-4-yl]-[3-(3-hydroxy-3-methylbutyl)phenyl]methanone Chemical compound CC(C)(O)CCC1=CC=CC(C(=O)C2=C(N(N=C2)C=2C=CC(F)=CC=2)N)=C1 VYZNEDVUQBPGQA-UHFFFAOYSA-N 0.000 claims 1
- UGLOHEBRMNZKKE-UHFFFAOYSA-N [5-amino-1-(4-fluorophenyl)pyrazol-4-yl]-[3-(3-morpholin-4-ylpropyl)phenyl]methanone Chemical compound NC1=C(C(=O)C=2C=C(CCCN3CCOCC3)C=CC=2)C=NN1C1=CC=C(F)C=C1 UGLOHEBRMNZKKE-UHFFFAOYSA-N 0.000 claims 1
- VSBKIQUFBDJXJL-UHFFFAOYSA-N [5-amino-1-(4-fluorophenyl)pyrazol-4-yl]-[3-(3-morpholin-4-ylpropylamino)phenyl]methanone Chemical compound NC1=C(C(=O)C=2C=C(NCCCN3CCOCC3)C=CC=2)C=NN1C1=CC=C(F)C=C1 VSBKIQUFBDJXJL-UHFFFAOYSA-N 0.000 claims 1
- BSNOOUBZAZNTTC-UHFFFAOYSA-N [5-amino-1-(4-fluorophenyl)pyrazol-4-yl]-[3-[2-(1-hydroxycyclopentyl)ethyl]phenyl]methanone Chemical compound NC1=C(C(=O)C=2C=C(CCC3(O)CCCC3)C=CC=2)C=NN1C1=CC=C(F)C=C1 BSNOOUBZAZNTTC-UHFFFAOYSA-N 0.000 claims 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 1
- 229960004748 abacavir Drugs 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 231100000354 acute hepatitis Toxicity 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 150000003974 aralkylamines Chemical group 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000005000 autoimmune gastritis Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- JEPPYVOSGKWVSJ-UHFFFAOYSA-N bicyclo[2.2.1]heptan-3-amine Chemical compound C1CC2C(N)CC1C2 JEPPYVOSGKWVSJ-UHFFFAOYSA-N 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 208000019664 bone resorption disease Diseases 0.000 claims 1
- 229930194791 calphostin Natural products 0.000 claims 1
- 208000001969 capillary hemangioma Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 claims 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000005265 dialkylamine group Chemical group 0.000 claims 1
- 125000005879 dioxolanyl group Chemical group 0.000 claims 1
- 238000006073 displacement reaction Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- IPSHHLCIDUEUIZ-UHFFFAOYSA-N ethyl 5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-3-(2-hydroxyethoxy)pyrazole-4-carboxylate Chemical compound N1=C(OCCO)C(C(=O)OCC)=C(N)N1C1=CC(C(=O)NC2CC2)=CC=C1C IPSHHLCIDUEUIZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000027950 fever generation Effects 0.000 claims 1
- 125000004175 fluorobenzyl group Chemical group 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229940076144 interleukin-10 Drugs 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 125000006178 methyl benzyl group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- DMEKUKDWAIXWSL-UHFFFAOYSA-N n,n-dimethyl-7-nitro-9h-fluoren-2-amine Chemical compound [O-][N+](=O)C1=CC=C2C3=CC=C(N(C)C)C=C3CC2=C1 DMEKUKDWAIXWSL-UHFFFAOYSA-N 0.000 claims 1
- RSECCHDABRGVNM-UHFFFAOYSA-N n-[3-(5-amino-1-phenylpyrazole-4-carbonyl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C(=O)C2=C(N(N=C2)C=2C=CC=CC=2)N)=C1 RSECCHDABRGVNM-UHFFFAOYSA-N 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 229960003753 nitric oxide Drugs 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 230000005937 nuclear translocation Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims 1
- 229950005741 rolipram Drugs 0.000 claims 1
- 201000005404 rubella Diseases 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000005113 shigellosis Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 claims 1
- 229960003676 tenidap Drugs 0.000 claims 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- RFIOKAVZMQCWMB-UHFFFAOYSA-N tert-butyl 2-[3-[5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]imidazole-4-carbonyl]phenoxy]acetate Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC=CC(OCC(=O)OC(C)(C)C)=C1 RFIOKAVZMQCWMB-UHFFFAOYSA-N 0.000 claims 1
- WSUTUXNKYYOLHT-UHFFFAOYSA-N tert-butyl 3-[5-amino-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]imidazole-4-carbonyl]benzoate Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)C=NC=1C(=O)C1=CC=CC(C(=O)OC(C)(C)C)=C1 WSUTUXNKYYOLHT-UHFFFAOYSA-N 0.000 claims 1
- JOKALNBSCASTJQ-UHFFFAOYSA-N tert-butyl 4-[5-amino-4-benzoyl-1-[5-(cyclopropylcarbamoyl)-2-methylphenyl]pyrazol-3-yl]oxypiperidine-1-carboxylate Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(=C1C(=O)C=2C=CC=CC=2)N)N=C1OC1CCN(C(=O)OC(C)(C)C)CC1 JOKALNBSCASTJQ-UHFFFAOYSA-N 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
Spoj formule: ili njegov farmaceutski prihvatljivi derivat, koji je njegova sol, njegov solvat ili hidrat, naznačen time, da: R1 je vodik, acil ili -P(O)(OH)2;R2 je vodik, halo, opcijski supstituiran alkil, alkiltio, alkilsulfinil, alkilsulfonil, opcijski supstituiran alkoksi, opcijski supstituiran heterocikliloksi ili alkilamino; G je aril, aralkil, cikloalkil, heteroaril, heteroaralkil ili heterociklilni prsten opcijski sjedinjen s fenilnim prstenom, i supstituiran je s R3 i R4, pod uvjetom da je heterociklilni prsten priključen na karbonilnu skupinu preko atoma ugljikovog prstena, ili G je OR83 ili NR81; B je aril ili heteroarilni prsten; C je pirazol ili imidazol; D je heteroaril, opcijski supstituiran heteroaril ili -C(O)NR80R81; svaki R80 i R81 je neovisno vodik, alkil, opcijski supstituiran cikloalkil, alkoksi, hidroksi, heteroaril ili opcijski supstituiran heteroaril, ili zajedno tvore opcijski supstituiran alkilen ili heteroalkilen; R83 je vodik, alkil, cikloalkil, heteroaril ili opcijski supstituirani heteroaril; R3 je odabran iz skupine koju čine: (a) amino, alkilamino ili dialkilamino; (b) acilamino; (c) opcijski supstituiran heterociklil; (d) opcijski supstituiran aril ili heteroaril; (e) heteroalkil; (f) heteroalkenil; (g) heteroalkinil; (h) heteroalkoksi; (i) heteroalkilamino; (j) opcijski supstituiran heterociklilalkil; (k) opcijski supstituiran heterociklilalkenil; (l) opcijski supstituiran heterociklilalkinil; (m) opcijski supstituiran heterociklilalkoksi ili heterocikliloksi; (n) opcijski supstituiran heterociklilalkilamino; (o) opcijski supstituiran heterociklilalkilkarbonil; (p) heteroalkilkarbonil; (q) -NHSO2R6 gdje R6 je alkil, heteroalkil ili opcijski supstituiran heterociklilalkil; (r) -NHSO2NR7R8 gdje R7 i R8 su međusobno neovisno vodik, alkil ili heteroalkil; (s) -Y-(alkilen)-R9 gdje: Y je jednostruka veza, -O-, -NH-ili -S(O)n- (gdje n je cijeli broj od 0 do 2); iR9 je halo, cijano, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran heterociklil, -COOH, -COR10, -COOR11, -CONR12R13, -SO2R14, -SO2NR15R16, -NHSO2R17 ili -NHSO2NR18R19, gdje R10 je alkil ili opcijski supstituiran heterocikl, R11 je alkil, te R12, R13, R14, R15, R16, R17, R18 i R19 su međusobno neovisno vodik, alkil ili heteroalkil; (t) -C(=NR20)(NR21R22) gdje R20, R21 i R22 neovisno predstavljaju vodik, alkil ili hidroksi, ili R20 i R21 su zajedno -(CH2)n- gdje n je 2 ili 3 te R22 je vodik ili alkil; (u) -NHC(X)NR23R24 gdje X je -O- ili -S-, a R23 i R24 su međusobno neovisno vodik, alkil ili heteroalkil; (v) -CONR25R26 gdje R25 i R26 neovisno predstavljaju vodik, alkil, heteroalkil ili opcijski supstituiran heterociklilalkil, ili R25 i R26 zajedno s dušikom na koji su priključeni tvore opcijski supstituiran heterociklilni prsten; (w) -S(O)nR27 gdje n je cijeli broj od 0 do 2, i R27 je alkil, heteroalkil, opcijski supstituiran heterociklilalkil ili -NR28R29 gdje R28 i R29 su međusobno neovisno vodik, alkil ili heteroalkil; (x)
Claims (114)
1. Spoj formule:
[image]
ili njegov farmaceutski prihvatljivi derivat, koji je njegova sol, njegov solvat ili hidrat, naznačen time, da:
R1je vodik, acil ili -P(O)(OH)2;
R2je vodik, halo, opcijski supstituiran alkil, alkiltio, alkilsulfinil, alkilsulfonil, opcijski supstituiran alkoksi, opcijski supstituiran heterocikliloksi ili alkilamino;
G je aril, aralkil, cikloalkil, heteroaril, heteroaralkil ili heterociklilni prsten opcijski sjedinjen s fenilnim prstenom, i supstituiran je s R3 i R4, pod uvjetom da je heterociklilni prsten priključen na karbonilnu skupinu preko atoma ugljikovog prstena, ili G je OR83 ili NR81;
B je aril ili heteroarilni prsten; C je pirazol ili imidazol;
D je heteroaril, opcijski supstituiran heteroaril ili -C(O)NR80R81; svaki R80i R81je neovisno vodik, alkil, opcijski supstituiran cikloalkil, alkoksi, hidroksi, heteroaril ili opcijski supstituiran heteroaril, ili zajedno tvore opcijski supstituiran alkilen ili heteroalkilen;
R83 je vodik, alkil, cikloalkil, heteroaril ili opcijski supstituirani heteroaril;
R3 je odabran iz skupine koju čine:
(a) amino, alkilamino ili dialkilamino;
(b) acilamino;
(c) opcijski supstituiran heterociklil;
(d) opcijski supstituiran aril ili heteroaril;
(e) heteroalkil;
(f) heteroalkenil;
(g) heteroalkinil;
(h) heteroalkoksi;
(i) heteroalkilamino;
(j) opcijski supstituiran heterociklilalkil;
(k) opcijski supstituiran heterociklilalkenil;
(l) opcijski supstituiran heterociklilalkinil;
(m) opcijski supstituiran heterociklilalkoksi ili heterocikliloksi;
(n) opcijski supstituiran heterociklilalkilamino;
(o) opcijski supstituiran heterociklilalkilkarbonil;
(p) heteroalkilkarbonil;
(q) -NHSO2R6 gdje R6 je alkil, heteroalkil ili opcijski supstituiran heterociklilalkil;
(r) -NHSO2NR7R8 gdje R7 i R8 su međusobno neovisno vodik, alkil ili heteroalkil;
(s) -Y-(alkilen)-R9 gdje: Y je jednostruka veza, -O-, -NH-ili -S(O)n- (gdje n je cijeli broj od 0 do 2); i
R9je halo, cijano, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran heterociklil, -COOH, -COR10, -COOR11, -CONR12R13, -SO2R14, -SO2NR15R16, -NHSO2R17 ili -NHSO2NR18R19, gdje R10 je alkil ili opcijski supstituiran heterocikl,
R11je alkil, te R12, R13, R14, R15, R16, R17, R18 i R19 su međusobno neovisno vodik, alkil ili heteroalkil;
(t) -C(=NR20)(NR21R22) gdje R20, R21i R22 neovisno predstavljaju vodik, alkil ili hidroksi, ili R20 i R21 su zajedno -(CH2)n- gdje n je 2 ili 3 te R22 je vodik ili alkil;
(u) -NHC(X)NR23R24 gdje X je -O- ili -S-, a R23 i R24 su međusobno neovisno vodik, alkil ili heteroalkil;
(v) -CONR25R26 gdje R25 i R26 neovisno predstavljaju vodik, alkil, heteroalkil ili opcijski supstituiran heterociklilalkil, ili R25 i R26 zajedno s dušikom na koji su priključeni tvore opcijski supstituiran heterociklilni prsten;
(w) -S(O)nR27 gdje n je cijeli broj od 0 do 2, i R27 je alkil, heteroalkil, opcijski supstituiran heterociklilalkil ili -NR28R29gdje R28i R29su međusobno neovisno vodik, alkil ili heteroalkil;
(x) cikloalkilalkil, cikloalkilalkinil i cikloalkilalkinil, svi opcijski supstituirani s alkilom, halo, hidroksi ili aminom;
(y) arilaminoalkilen ili heteroarilaminoalkilen;
(z) Z-alkilen-NR30R31 ili Z-alkilen-OR32 gdje Z je -NH-, -N(niži alkil)- ili -O-, i R30, R31 i R32su međusobno neovisno vodik, alkil ili heteroalkil;
(aa) -OC(O)-alkilen-CO2H ili -OC(O)-NR'R'' gdje R' i R" su neovisno vodik ili alkil;
(bb) heteroarilalkenilen ili heteroarilalkinilen;
(cc) vodik;
(dd) halo;
(ee) pseudohalo;
(ff) hidroksi;
(gg) opcijski supstituiran alkoksi;
(hh) C(L)R40, gdje L je O, S ili NR55; R40 je vodik, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran heteroarilij, opcijski supstituiran cikloalkil, opcijski supstituiran heterociklil, C(L)R56, halo pseudohalo, OR55, SR55, NR57R58ili SiR52R53R54; gdje R52 R53 i R54 su odabrani kao u (i) ili (ii) kako slijedi
(i) R52, R53 i R54 su svaki neovisno vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil, OR55 ili NR62R63;
ili (ii) bilo koja dva od R52, R53 i R54 zajedno tvore alkilen, alkenilen, alkinilen, heteroalkilen;
a preostali je odabran kao u (i);
R55je vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil ili heterociklil;
R56je vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil, OR55ili NR64R65; gdje R64 i R65 su svaki neovisno vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil, OR66 ili NR62R63, ili R64i R65 zajedno tvore alkilen, alkenilen, alkinilen, heteroalkilen, gdje R66 je vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil ili heterociklil;
R57 i R58su odabrani kao u (i) ili (ii) kako slijedi
(i) R57 i R58su svaki neovisno vodik, opcijski supstituiran alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil, OR55, NR67R68ili C(L)R69, gdje R67 i R68su svaki neovisno vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil ili heterociklil, ili zajedno tvore alkilen, alkenilen, alkinilen, heteroalkilen;
i R69 je vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil, OR70ili NR62R63, gdje R70 je alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil;
ili (ii) R57 i R58 zajedno tvore alkilen, alkenilen, alkinilen, heteroalkilen ili alkilenoksialkilen;
R62i R63 su svaki neovisno vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil, ili R62 i R63 zajedno tvore alkilen, alkenilen, alkinilen, heteroalkilen;
(ii) opcijski supstituiran alkil; i
(jj) cijano;
R4 je odabran iz skupine koju čine:
(a) vodik;
(b) halo;
(c) alkil;
(d) alkoksi; i
(e) hidroksi;
ili R3 i R4, koji zamjenjuju susjedne atome na prstenu, zajedno tvore alkilendioksi, tioalkilenoksi ili alkilenditioksi;
R5 je odabran iz skupine koju čine:
(a) vodik;
(b) halo;
(c) alkil;
(d) haloalkil;
(e) tioalkil;
(f) hidroksi;
(g) amino;
(h) alkilamino;
(i) dialkilamino;
(j) heteroalkil;
(k) opcijski supstituiran heterocikl;
(l) opcijski supstituiran heterociklilalkil;
(m) opcijski supstituiran heterociklilalkoksi;
(n) alkilsulfonil;
(o) aminosulfonil, mono-alkilaminosulfonil ili di-alkilaminosulfonil;
(p) heteroalkoksi; i
(q) karboksi;
R6 je odabran iz skupine koju čine:
(a) vodik;
(b) halo;
(c) alkil; i
(d) alkoksi.
2. Spoj prema zahtjevu 1, naznačen time, da G je OR83 ili NR8R81.
3. Spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time, da R83 je alkil or cikloalkil.
4. Spoj prema bilo kojem zahtjevu 1 do 3, naznačen time, da R83 je alkil.
5. Spoj prema bilo kojem zahtjevu 1 do 4, naznačen time, da R83 je etil.
6. Spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time, da R80 i R81 su svaki neovisno vodik, opcijski supstituiran alkil ili opcijski supstituiran cikloalkil, ili zajedno tvore opcijski supstituiran alkilen ili opcijski supstituiran heteroalkilen.
7. Spoj prema bilo kojem zahtjevu 1, 2 i 6, naznačen time, da R80 i R81 su svaki neovisno vodik ili opcijski supstituirani cikloalkil.
8. Spoj prema bilo kojem zahtjevu 1, 2, 6 i 7, naznačen time, da R80 i R81 su svaki neovisno vodik, cikloheksil, 2-metilcikloheksil, 3-pentil, biciklo[2.2.1]heptil, 1-etinilcikloheksil, metoksibenzil, benzil, indanil, ciklopropil, 3-klorobenzil, ciklopentil, 2,4-diklorobenzil, cikloheksilmetil, 3,4-diklorobenzil, 4-metilcikloheksil, 3-trifluorometilbenzil, 4-tert-butilcikloheksil, neopentil, fluorobenzil, N-etil-2-pirolidinilmetil, metilbenzil, piridilmetil, morfoliniletil, 1-cikloheksiletil, 1-feniletil ili 2-pirolidiniletil; ili R80 i R81 zajedno tvore pentilen ili 2,5-heksilen.
9. Spoj prema bilo kojem zahtjevu 1, 2 i 6 do 8, naznačen time, da G je NH2 ili NH(cikloheksil).
10. Spoj prema zahtjevu 1, naznačen time, da G je aril, heteroaril, cikloalkil, heterociklil ili heterociklil opcijski sjedinjen s fenilom, i supstituiran je s R3 i R4, uz uvjet da je heterociklilni prsten priključen na karbonilnu skupinu preko atoma ugljikovog prstena.
11. Spoj prema zahtjevu 1 ili zahtjevu 10, naznačen time, da G je fenil, piridil, cikloheksil, ciklopentil ili benzil, i supstituiran je s R3 i R4.
12. Spoj prema bilo kojem zahtjevu 1, 10 ili 11, naznačen time, da G je fenil i supstituiran je s R3 i R4.
13. Spoj prema bilo kojem zahtjevu 1 ili 10 do 12, naznačen time, da ima formulu (I):
[image]
gdje:
A odgovara G u formuli zahtjeva 1, pri čemu A je aril, heteroaril, cikloalkil ili heterociklilni prsten opcijski sjedinjen s fenilnim prstenom, uz uvjet da je heterociklilni prsten priključen na karbonilnu skupinu preko atoma ugljikovog prstena.
14. Spoj prema bilo kojem zahtjevu 1 do 13, naznačen time, da C je imidazolni prsten.
15. Spoj prema bilo kojem zahtjevu 1 do 13, naznačen time, da C je pirazolni prsten.
16. Spoj prema bilo kojem zahtjevu 1 do 13, naznačen time, da spoj ima formulu II:
[image]
ili njegov farmaceutski prihvatljiv derivat, kako je određeno u zahtjevu 1, pri čemu prsten NH skupine može biti zamijenjen jednim od sljedećih supstituenata: -C(O)-A(R3)(R4), -R2, ili -B(D)(R6)(R5) i A odgovara G u formuli zahtjeva 1.
17. Spoj prema bilo kojem zahtjevu 1 do 13, 15 i 16, naznačen time, da spoj ima formulu III:
[image]
gdje A odgovara G u formuli zahtjeva 1;
ili njegov farmaceutski prihvatljiv derivat kako je određeno u zahtjevu 1.
18. Spoj prema bilo kojem zahtjevu 1 do 13, 15 i 16, naznačen time, da spoj ima formulu IV:
[image]
gdje A odgovara G u formuli zahtjeva 1;
ili njegov farmaceutski prihvatljiv derivat kako je određeno u zahtjevu 1.
19. Spoj prema bilo kojem zahtjevu 1 do 13, 15 i 16, naznačen time, da spoj ima formulu V:
[image]
gdje A odgovara G u formuli zahtjeva 1;
ili njegov farmaceutski prihvatljiv derivat kako je određeno u zahtjevu 1.
20. Spoj prema bilo kojem zahtjevu 1 do 13, 15 i 16, naznačen time, da spoj ima formulu Va:
[image]
gdje A odgovara G u formuli zahtjeva 1;
ili njegov farmaceutski prihvatljiv derivat kako je određeno u zahtjevu 1.
21. Spoj prema bilo kojem zahtjevu 1 do 14, naznačen time, da spoj ima formulu VI:
[image]
ili njegov farmaceutski prihvatljiv derivat kako je određeno u zahtjevu 1, pri čemu se prsten NH skupine može zamijeniti jednim od sljedećih supstituenata: -C(O)-A(R3)(R4), -R2 ili -B(D)(R6)(R5) i A odgovara G u formuli zahtjeva 1.
22. Spoj prema bilo kojem zahtjevu 1 do 14 i 21, naznačen time, da spoj ima formulu VII:
[image]
gdje A odgovara G u formuli zahtjeva 1;
ili njegov farmaceutski prihvatljiv derivat kako je određeno u zahtjevu 1.
23. Spoj prema bilo kojem zahtjevu 1 do 14 i 21, naznačen time, da spoj ima formulu VIII:
[image]
gdje A odgovara G u formuli zahtjeva 1;
ili njegov farmaceutski prihvatljiv derivat kako je određeno u zahtjevu 1.
24. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R1 je vodik.
25. Spoj prema bilo kojem zahtjevu 1 do 24, naznačen time, da R2 je vodik ili niži alkil.
26. Spoj prema bilo kojem zahtjevu 1 do 25, naznačen time, da R2 je vodik, metil, n-propil ili 3-klorobenzilaminokarbonilmetoksi.
27. Spoj prema bilo kojem zahtjevu 1 do 26, naznačen time, da G ili A je arilni prsten.
28. Spoj prema bilo kojem zahtjevu 1 do 27, naznačen time, da G ili A je fenilni prsten.
29. Spoj prema bilo kojem zahtjevu 1 do 28, naznačen time, da B je arilni prsten.
30. Spoj prema bilo kojem zahtjevu 1 do 29, naznačen time, da B je fenilni prsten.
31. Spoj prema bilo kojem zahtjevu 1 do 30, naznačen time, da D je -C(O)NR80R81.
32. Spoj prema bilo kojem zahtjevu 1 do 31, naznačen time, da R80i R81su svaki neovisno vodik, cikloalkil ili alkoksi.
33. Spoj prema bilo kojem zahtjevu 1 do 32, naznačen time, da R80 je vodik.
34. Spoj prema bilo kojem zahtjevu 1 do 33, naznačen time, da R81 je cikloalkil ili alkoksi.
35. Spoj prema bilo kojem zahtjevu 1 do 34, naznačen time, da R81 je C3-6cikloalkil ili C1-6alkoksi.
36. Spoj prema bilo kojem zahtjevu 1 do 35, naznačen time, da R81 je ciklopropil ili metoksi.
37. Spoj prema bilo kojem zahtjevu 1 do 30, naznačen time, da D je opcijski supstituiran heteroaril.
38. Spoj prema bilo kojem zahtjevu 1 do 30 i 37, naznačen time, da D je opcijski supstituiran triazolil.
39. Spoj prema bilo kojem zahtjevu 1 do 30, 37 i 38, naznačen time, da D je 1,2,4-triazol-3-il.
40. Spoj prema bilo kojem zahtjevu 1 do 39, naznačen time, da R3 je vodik, opcijski supstituiran heterociklil, opcijski supstituiran alkil, C(L)R40, halo, pseudohalo ili OR41; gdje L je O, S ili NR55;
R40je vodik, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran heteroarilij, opcijski supstituiran cikloalkil, opcijski supstituiran heterociklil, C(L)R56, halo, pseudohalo, OR55, SR55, NR57R58ili SiR52R53R54;
R41 je vodik, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran heteroarilij, opcijski supstituiran cikloalkil, opcijski supstituiran heterociklil, C(L)R59, NR60R61 ili SiR52R53R54; gdje
R52, R53 i R54 su odabrani kao u (i) ili (ii) kako slijedi:
(i) R52, R53 i R54su svaki neovisno vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil, OR55 ili NR62R63; ili
(ii) bilo koji od R52, R53 i R54 zajedno tvore alkilen, alkenilen, alkinilen, heteroalkilen; a preostali je odabran kao u (i);
R55 je vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil ili heterociklil;
R56 je vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil, OR55 ili NR64R65; gdje R64 i R65 su svaki neovisno vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil, OR66 ili NR62R63, ili R64 i R65 zajedno tvore alkilen, alkenilen, alkinilen, heteroalkilen, gdje R66 je vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil ili heterociklil; R57 i R58 su odabrani kao u (i) ili (ii) kako slijedi:
(i) R57 i R58 su svaki neovisno vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil, OR55, NR67R68ili C(L)R69, gdje R67 i R68 su svaki neovisno vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil ili heterociklil, ili zajedno tvore alkilen, alkenilen, alkinilen, heteroalkilen; i R69je vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil, OR70 ili NR62R63, gdje R70 je alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil; or
(ii) R57i R58zajedno tvore alkilen, alkenilen, alkinilen, heteroalkilen;
R59je vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil, OR70 ili NR62R63 ;
R60i R61 su svaki neovisno vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil ili C(L)R71 gdje R71 je alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil, OR55 ili NR62R63 ; ili R60 i R61 zajedno tvore alkilen, alkenilen, alkinilen, heteroalkilen;
R62 i R63 su svaki neovisno vodik, alkil, alkenil, alkinil, aril, heteroaril, heteroarilij, cikloalkil, heterociklil, ili R62 i R63 zajedno tvore alkilen, alkenilen, alkinilen, heteroalkilen.
41. Spoj prema bilo kojem zahtjevu 1 do 40, naznačen time, da R3 je vodik, opcijski supstituiran heterociklil, opcijski supstituiran alkil, C(L)R40, halo, cijano, opcijski supstituiran heteroaril, S(O)nR27 ili OR41.
42. Spoj prema bilo kojem zahtjevu 1 do 41, naznačen time, da R3 je vodik, opcijski supstituiran heterociklil, cijano, opcijski supstituiran heteroaril, opcijski supstituiran alkil, C(L)R40, jod, klor, fluor, S(O)nR27 ili OR41.
43. Spoj prema bilo kojem zahtjevu 1 do 42, naznačen time, da R3 je vodik, opcijski supstituiran dioksolanil, pirimidinil, piridil, pirazinil, cijano, oksadiazolil, triazolil, metiltio, metansulfonil, opcijski supstituiran metil, C(L)R40, jod, klor ili OR41.
44. Spoj prema bilo kojem zahtjevu 1 do 43, naznačen time, da R3je vodik, 2-dioksolanil, pirimidinil, piridil, pirazinil, cijano, oksadiazolil, triazolil, metiltio, metansulfonil, opcijski supstituiran metil, C(O)R40, jod, klor ili opcijski supstituiran metoksi.
45. Spoj prema bilo kojem zahtjevu 1 do 44, naznačen time, da R3je vodik, 2-dioksolanil, pirimidinil, piridil, pirazinil, cijano, oksadiazolil, triazolil, metiltio, metansulfonil, 5-metiloksadiazolil, metil, CHO, jod, klor, metoksi, benziloksi, etoksi, ciklopropoksi, t-butoksikarbonilbutoksi ili karbamoilmetoksi.
46. Spoj prema bilo kojem zahtjevu 1 do 45, naznačen time, da R3 je opcijski supstituiran metil.
47. Spoj prema bilo kojem zahtjevu 1 do 46, naznačen time, da R3 je metil koji je opcijski supstituiran s heterociklilom, hidroksi, aralkilaminom ili heterociklilalkilaminom.
48. Spoj prema bilo kojem zahtjevu 1 do 47, naznačen time, da R3je N-morfolinilmetil, hidroksimetil, N-(2-(3-klorofenil)-1-etil)aminometil, N-(2-morfolinil-1-etil)aminometil, (3-kloro-benzilamino)-metil, 4-(3-kloro-fenil)-piperazin-1-ilmetil, [2-(2-benziloksi-5-kloro-fenil)-etilamino]-metil, (3-morfolin-4-il-propilamino)-metil, karbamoilmetoksi, 2-(4-metil-piperazin-1-il)-2-okso-etoksi, 2-okso-2-piperazin-1-il-etoksi, 2-(3-amino-pirolidin-1-il)-2-okso-etoksi, 2-(3-metilamino-pirolidin-1-il)-2-okso-etoksi, 2-(3,5-dimetil-piperazin-1-il)-2-okso-etoksi, 2-morfolin-4-il-2-okso-etoksi, [(1H-benzoimidazol-2-ilmetil)-karbamoil]-metoksi, [2-(2-benziloksi-5-kloro-fenil)-etilkarbamoil]-metoksi, [2-(5-kloro-2-hidroksi-fenil)-etilkarbamoil]-metoksi ili 4-piperizinilmetil.
49. Spoj prema bilo kojem zahtjevu 1 do 48, naznačen time, da L je O.
50. Spoj prema bilo kojem zahtjevu 1 do 49, naznačen time, da R40je vodik, opcijski supstituiran alkil, opcijski supstituiran alkoksi, NR57R58 ili cikloalkil.
51. Spoj prema bilo kojem zahtjevu 1 do 50, naznačen time, da R40 je vodik, alkil, alkoksi ili NR57R58.
52. Spoj prema bilo kojem zahtjevu 1 do 51, naznačen time, da R40 je vodik, ciklopropilamino, NH2, izopropilamino, metilamino, piperazinil, dimetilamino, ciklopropilmetilamino, etilamino, ciklopentilamino ili tert-butoksi.
53. Spoj prema bilo kojem zahtjevu 1 do 52, naznačen time, da R41 je vodik, opcijski supstituiran alkenil, ili opcijski supstituiran alkil.
54. Spoj prema bilo kojem zahtjevu 1 do 53, naznačen time, da R41 je vodik, ili alkil ili alkenil svaki opcijski supstituiran s heterociklilom, arilom, heteroarilom, dialkilaminom, halo ili hidroksi.
55. Spoj prema bilo kojem zahtjevu 1 do 54, naznačen time, da R41 je vodik, ili C1-3alkil ili C1-3alkenil svaki opcijski supstituiran s heterociklilom, fenilom, heteroarilom, dialkilaminoom, halo ili hidroksi.
56. Spoj prema bilo kojem zahtjevu 1 do 55, naznačen time, da R41 je vodik, 2-(N-morfolinil)-1-etil, benzil, 2-(N,N-di-(2-hidroksi-1-etil)amino)-1-etil, 2-bromo-1-etil, 2,2-dioksolan-4-ilmetil, 2-(4-metilpiperazin-1-il)-1-etil, oksa-diazolilmetil, etenil, 2-dimetilaminoetil, 4-klorofenoksietil ili 2,3-dihidroksi-1-propil.
57. Spoj prema bilo kojem zahtjevu 1 do 56, naznačen time, da R41 je (S)-2,3-dihidroksi-1-propil.
58. Spoj prema bilo kojem zahtjevu 1 do 57, naznačen time, da R4 je vodik.
59. Spoj prema bilo kojem zahtjevu 1 do 58, naznačen time, da R5 je alkil.
60. Spoj prema bilo kojem zahtjevu 1 do 59, naznačen time, da R5 je metil.
61. Spoj prema bilo kojem zahtjevu 1 do 60, naznačen time, da R6 je vodik.
62. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da:
R1 je vodik, acil ili -P(O)(OH)2;
R2 je vodik, halo, alkil ili alkiltio;
G ili A je aril, heteroaril ili heterociklilni prsten opcijski sjedinjen s fenilim prstenom uz uvjet da je heterociklilni prsten priključen na karbonilnu skupinu preko atoma ugljikovog prstena;
B je arilni ili heteroarilni prsten;
D je heteroaril, opcijski supstituiran heteroaril ili -C(O)NR80R81 , (gdje R80 i R81 su neovisno vodik, alkil, cikloalkil, alkoksi, hidroksi, heteroaril ili opcijski supstituiran heteroaril);
R3 je odabran iz skupine koju čine:
(a) amino, alkilamino ili dialkilamino;
(b) acilamino;
(c) opcijski supstituiran heterociklil;
(d) opcijski supstituiran aril ili heteroaril;
(e) heteroalkil;
(f) heteroalkenil;
(g) heteroalkinil;
(h) heteroalkoksi;
(i) heteroalkilamino;
(j) opcijski supstituiran heterociklilalkil;
(k) opcijski supstituiran heterociklilalkenil;
(l) opcijski supstituiran heterociklilalkinil;
(m) opcijski supstituiran heterociklilalkoksi ili heterocikliloksi;
(n) opcijski supstituiran heterociklilalkilamino;
(o) opcijski supstituiran heterociklilalkilkarbonil;
(p) heteroalkilkarbonil;
(q) -NHSO2R6 gdje R6 je alkil, heteroalkil ili opcijski supstituiran heterociklilalkil;
(r) -NHSO2NR7R8 gdje R7 i R8 su međusobno neovisno vodik, alkil ili heteroalkil;
(s) -Y-(alkilen)-R9 gdje: Y je jednostruka veza, -O-, -NH- ili -S(O)n (gdje n je cijeli broj od 0 do 2); i R9 je cijano, opcijski supstituiran heteroaril, -COOH, -COR10, -COOR11, -CONR12R13, -SO2R14, -SO2NR15R16, -NHSO2R17 ili -NHSO2NR18R19, gdje R10 je alkil ili opcijski supstituiran heterocikl, R11 je alkil, a R12, R13, R14, R15, R16 , R17, R18 i R19 su međusobno neovisno vodik, alkil ili heteroalkil;
(t) -C(=NR20)(NR21R22) gdje R20, R21i R22neovisno predstavljaju vodik, alkil ili hidroksi, ili su R20 i R21 zajedno -(CH2)n- gdje n je 2 ili 3 i R22 je vodik ili alkil;
(u) -NHC(X)NR23)R24 gdje X je -O- ili -S-, i R23 i R24 su međusobno neovisno vodik, alkil ili heteroalkil;
(v) -CONR225R26 gdje R25 i R26 neovisno predstavljaju vodik, alkil, heteroalkil ili opcijski supstituiran heterociklilalkil, ili R25 i R26 zajedno s dušikom na koji su priključeni tvore opcijski supstituiran heterociklilni prsten;
(w) -S(O)nR27 gdje n je cijeli broj od 0 do 2, i R27 je alkil, heteroalkil, opcijski supstituiran heterociklilalkil ili -NR28R29gdje R28i R29su međusobno neovisno vodik, alkil ili heteroalkil;
(x) cikloalkilalkil, cikloalkilalkinil i cikloalkilalkinil, svi opcijski supstituirani s alkilom, halo, hidroksi ili aminom;
(y) arilaminoalkilen ili heteroarilaminoalkilen;
(z) Z-alkilen-NR30R31 ili Z-alkilen-OR32 gdje Z je -NH-, -N(niži alkil)- ili -O-, i R30, R31i R32su međusobno neovisno vodik, alkil ili heteroalkil;
(aa) -OC(O)-alkilen-CO2H ili -OC(O)-NR'R" (gdje R' i R" su neovisno vodik ili alkil);
i
(bb) heteroarilalkenilen ili heteroarilalkinilen;
R4 je odabran iz skupine koju čine:
(a) vodik;
(b) halo;
(c) alkil;
(d) alkoksi; i
(e) hidroksi;
R5 je odabran iz skupine koju čine:
(a) vodik;
(b) halo;
(c) alkil;
(d) haloalkil;
(e) tioalkil;
(f) hidroksi;
(g) amino;
(h) alkilamino;
(i) dialkilamino;
(j) heteroalkil;
(k) opcijski supstituiran heterocikl;
(l) opcijski supstituiran heterociklilalkil;
(m) opcijski supstituiran heterociklilalkoksi;
(n) alkilsulfonil;
(o) aminosulfonil, mono-alkilaminosulfonil ili dialkilaminosulfonil;
(p) heteroalkoksi; i
(q) karboksi;
R6 je odabran iz skupine koju čine:
(a) vodik;
(b) halo;
(c) alkil; i
(d) alkoksi;
individualni izomeri, smjese izomera i njegovih farmaceutski prihvatljivih soli.
63. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da:
R1 je vodik ili acil;
R2 je vodik ili alkil; i
G ili A je arilni ili heteroarilni prsten.
64. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da:
R1 je vodik, acil ili -P(O)(OH)2;
R2 je vodik, halo, alkil ili alkiltio;
G ili A je aril, heteroaril ili heterociklilni prsten opcijski sjedinjen na fenilni prsten uz uvjet da je heterociklilni prsten priključen na karbonilnu skupinu preko atoma ugljikovog prstena;
B je arilni ili heteroarilni prsten;
R3 je odabran iz skupine koju čine:
(a) amino;
(b) acilamino;
(c) opcijski supstituiran heterocikl;
(d) heteroaril opcijski supstituiran sa supstituentom odabranim od halo, alkil ili alkoksi;
(e) heteroalkil;
(f) heteroalkenil;
(g) heteroalkinil;
(h) heteroalkoksi;
(i) heteroalkilamino;
(j) opcijski supstituiran heterociklilalkil;
(k) opcijski supstituiran heterociklilalkenil;
(l) opcijski supstituiran heterociklilalkinil;
(m) opcijski supstituiran heterociklilalkoksi;
(n) opcijski supstituiran heterociklilalkilamino;
(o) opcijski supstituiran heterociklilalkilkarbonil;
(p) heteroalkilkarbonil;
(q) -NHSO2R6, gdje R6 je alkil, heteroalkil ili opcijski supstituiran heterociklilalkil;
(r) -NHSO2NR7R8 gdje R7 i R8 su međusobno neovisno vodik, alkil ili heteroalkil;
(s) -Y-(alkilen)-R9 gdje: Y je jednostruka veza, -O-, -NH -ili -S(O)n-(gdje n je cijeli broj od 0 do 2); i R9 je cijano, heteroaril, -COOH, -COR10, -COOR11, -CONR12R13, -SO2R14, -SO2NR15SR16, -NHSO2R17 ili -NHSO2NR18R19 gdje R10 je alkil ili opcijski supstituiran heterocikl, R11 je alkil, a R12, R13, R14, R15, R16, R17, R18 i R19 su međusobno neovisno vodik, alkil ili heteroalkil;
(t) -C(=NR20)(NR21R22) gdje R20,R21 i R22 neovisno predstavljaju vodik, alkil ili hidroksi, ili su R20 i R21 zajedno -(CH2)n- gdje n je 2 ili 3 i R22 je vodik ili alkil;
(u) -NHC(X)NR23R24 gdje X je -O- ili -S-, i R23 i R24 su međusobno neovisno vodik, alkil ili heteroalkil;
(v) -CONR25R26, gdje R25 i R26 neovisno predstavljaju vodik, alkil, heteroalkil ili opcijski supstituiran heterociklilalkil, ili R25 i R26 zajedno s dušikom na koji su priključeni tvore opcijski supstituiran heterociklilni prsten;
(w) -S(O)nR27 gdje n je cijeli broj od 0 do 2, i R27 je alkil, heteroalkil, opcijski supstituiran heterociklilalkil ili -NR28R29gdje R28i R29su međusobno neovisno vodik, alkil ili heteroalkil;
R4 je odabran iz skupine koju čine:
(a) vodik;
(b) halo;
(c) alkil; i
(d) alkoksi;
R5 je odabran iz skupine koju čine:
(a) vodik;
(b) halo;
(c) alkil;
(d) haloalkil;
(e) tioalkil;
(f) hidroksi;
(g) amino;
(h) alkilamino;
(i) dialkilamino;
(j) heteroalkil;
(k) opcijski supstituiran heterocikl;
(l) opcijski supstituiran heterociklilalkil; i
(m) opcijski supstituiran heterociklilalkoksi;
R6 je odabran iz skupine koju čine:
(a) vodik;
(b) halo;
(c) alkil; i
(d) alkoksi.
65. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R3 je:
(a) opcijski supstituiran heterociklil;
(b) aril ili heteroaril oba opcijski supstituirana sa supstituentom odabranim od halo, alkil, amino, alkoksi, karboksi, niži alkoksi karbonil, SO2R' (gdje R' je alkil) ili -O2NHR'R" (gdje R' i R" su neovisno vodik ili alkil);
(c) heteroalkil;
(d) heteroalkenil;
(e) heteroalkilamino;
(f) heteraloksi;
(g) opcijski supstituiran heterociklilalkil ili heterocikliloksi;
(h) opcijski supstituiran heterociklilalkenil;
(i) opcijski supstituiran heterociklilalkinil;
(j) opcijski supstituiran heterociklilalkoksi;
(k) opcijski supstituiran heterociklilalkilamino;
(l) opcijski supstituiran heterociklilalkilkarbonil:
(s) -Y-(alkilen)-R9gdje Y je jednostruka veza, -O- ili -NH- i R9je opcijski supstituiran heteroaril, -CONR12R13, SO2R14, -SO2NR15R16-NHSO2R17 ili -NHSO2 NR18R19gdje R12, R13, R14, R15, R16, R17, R18 i R19 su međusobno neovisno heteroalkil, vodik, alkil ili heteroalkil;
(x) cikloalkilalkil, cikloalkilalkinil i cikloalkilalkinil, svi opcijski supstituirani s alkilom, halo, hidroksi ili aminom;
(m) arilaminoalkilen ili heteroarilaminoalkilen; ili
(n) Z-alkilen-NR30R31 gdje Z je -NH-, -N(alkil)- ili -O-, a R30 i R31 su međusobno neovisno vodik, alkil ili heteroalkil.
66. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R1 i R2 su vodik i B je fenil.
67. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R4 je vodik i R5 je halo ili alkil.
68. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R5 je klor, fluor ili metil i R6 je vodik, klor, fluor, metil ili metoksi.
69. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R3 je opcijski supstituiran heteroaril.
70. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R3 je piridin-2-il, piridin-3-il, piridin-4-il, N-oksidopiridin-2-il, N-oksidopiridin-3-il, N-oksidopiridin-4-il ili piridon-2-il, svi opcijski supstituirani.
71. Spoj prema bilo kojem zahtjevu 1 do 70, naznačen time, da R3 je na poziciji 3.
72. Spoj prema bilo kojem zahtjevu 1 do 71, naznačen time, da R5 je 4-F ili 2-Me, a R6 je vodik.
73. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R3 je opcijski supstituiran fenil.
74. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R3je 3-sulfamoilfenil, 3-metilsulfonilfenil, 3-karboksifenil ili 3-etoksikarbonilfenil.
75. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R5 je 4-F i R6 je vodik.
76. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R3 je:
(a) heteroalkil;
(b) heteroalkoksi;
(c) heteroalkilamino;
(d) opcijski supstituiran heterociklilalkil;
(e) opcijski supstituiran heterociklilalkoksi;
(f) opcijski supstituiran heterociklilalkilamino;
(g) Y-(alkilen)-R9gdje Y je jednostruka veza, -O- ili -NH-i R9je opcijski supstituiran heteroaril, -CONR12R13, -SO1R14, -SONR15R16-NHSO2R17 ili -NHSO2NR18R19gdje R12, R13, R14, R15,R16, R17, R18 i R19 su međusobno neovisno vodik, alkil ili heteroalkil;
ili
(h) Z-alkilen-NR30R31 gdje Z je -NH-, -N(alkil)- ili -O-, i R30 i R31 su međusobno neovisno vodik, alkil ili heteroalkil.
77. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R3 je heteroalkil.
78. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R3 je na poziciji 3 i odabran je iz skupine koja sadrži 2-dimetilaminoetil, 3-dimetilaminopropil, 4-dimetilaminobutil, 2-dimetilaminoetilamino, 3-dimetilaminopropilamino, hidroksimetil, 1,2-dihidroksietil, 3-hidroksi-3-metil-1-butil ili 3-hidroksibutil.
79. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R5 je 2-F i R6 je 4-F.
80. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R5 je 2-Me i R6 je vodik.
81. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R9 je heteroalkoksi ili heteroalkilamino.
82. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R3 je na poziciji 3 i odabran je iz skupine koja sadrži 3-dimetilaminopropoksi, 2-dimetilaminoetoksi, 2-hidroksietoksi, 2,3-dihidroksipropoksi, 2-dimetilaminoetilamino i 3-dimetilaminopropilamino.
83. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R3je opcijski supstituiran heterociklilalkil, opcijski supstituiran heterociklilalkoksi ili opcijski supstituiran heterociklilalkilamino.
84. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R3 je na poziciji 3 i odabran je iz skupine koja sadrži 3-(morfolin-4-il)propoksi, 2-(morfolin-4-il)etoksi, 2-(2-okso-pirolidin-1-il)etoksi, 3(morfolin-4-il)propil, 2-(morfolin-4-il)etil, 4-(morfolin-4-il)butil, 3-(morfolin-4-il)propilamino, 2-(morfolin-4-il)etilamino, 4-hidroksipiperidinilmetil, 2-(S,S-dioksotiamorfolin-4-il)etil, 3-(S,S-dioksotiamorfolin-4-il)propil i N-metilpiperazinilmetil.
85. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R3 je -Y-(alkilen)-R9 gdje Y je jednostruka veza, -O- ili -NH- i R9 je opcijski supstituiran heteroaril, -CONR12R13, -SO2R14, -SO2NR15R16, -NHSO2R17 ili -NHSO2NR18R19 gdje R12, R13, R14, R15, R16, R17 R18 i R19 su međusobno neovisno vodik, alkil ili heteroalkil.
86. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da Y je jednostruka veza i R9 je -SO2R14 ili -SO2NR15R16.
87. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R3 je 5-metilsulfoniletil ili sulfamoiletil.
88. Spoj prema bilo kojem zahtjevu 1 do 87, naznačen time, da je odabran od:
3-[5-amino-4-(3-jodo-benzoil)-pirazol-1-il]-N-metoksi-4-metil-benzamid;
3-(5-amino-4-benzoil-pirazol-1-il)-N-metoksi-4-metil-benzamid;
3-(5-amino-4-benzoil-pirazol-1-il)-4-metil-benzoična kiselina;
3-(5-amino-4-benzoil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-jodo-benzoil)-pirazol-1-il]-4-metil-benzoična kiselina;
3-[5-amino-4-(3-jodo-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
{5-amino-1-[2-metil-5-(4H-[1,2,4]triazol-3-il)-fenil]-1H-pirazol-4-il}-fenil-metanon;
3-[5-amino-4-(3-[1,3]dioksolan-2-il-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-formil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-hidroksimetil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-{5-amino-4-[3-(4-metil-piperazin-1-ilmetil)-benzoil]-pirazol-1-il}-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-morfolin-4-ilmetil-benzoil)-pirazol-1- N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-morfolin-4-ilmetil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-benziloksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-hidroksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(4-metil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid; i
3-(5-amino-4-benzoil-imidazol-1-il)-N-ciklopropil-4-metil-benzamid.
89. Spoj prema bilo kojem zahtjevu 1 do 88, naznačen time, da je odabran od:
3-[5-amino-4-(3-jodo-benzoil)-pirazol-1-il]-N-metoksi-4-metil-benzamid;
3-(5-amino-4-benzoil-pirazol-1-il)-N-metoksi-4-metil-benzamid;
3-(5-amino-4-benzoil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-jodo-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
{5-amino-1-[2-metil-5-(4H-[1,2,4]triazol-3-il)-fenil]-1H-pirazol-4-il}-fenil-metanon;
3-[5-amino-4-(3-[1,3]dioksolan-2-il-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-formil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-hidroksimetil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-{5-amino-4-[3-(4-metil-piperazin-1-ilmetil)-benzoil]-pirazol-1-il}-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-morfolin-4-ilmetil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-morfolin-4-ilmetil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-benziloksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-hidroksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(4-metil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid; ili
3-(5-amino-4-benzoil-imidazol-1-il)-N-ciklopropil-4-metil-benzamid.
90. Spoj prema bilo kojem zahtjevu 1 do 89, naznačen time, da je to 3-(5-amino-4-benzoil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid.
91. Spoj prema bilo kojem zahtjevu 1 do 87, naznačen time, da je odabran od:
5-amino-1-(4-fluorofenil)-4-[3-(2-morfolin-4-iletoksi)benzoil]pirazol;
5-amino-1-(2,4-difluorofenil)-4-[3-(3-morfolin-4-ilpropil)benzoil]pirazol;
5-amino-4-(3-aminobenzoil)-1-(4-fluorofenil)pirazol;
5-amino-1-(4-fluorofenil)-4-[3-(3-morfolin-4-ilpropil)benzoil]pirazol;
5-amino-4-[3-(2-aminosulfoniletenil)benzoil]-1-(4-fluorofenil)pirazol;
5-amino-4-(3-acetilaminobenzoil)-1-fenilpirazol;
5-amino-4-[3-(2-aminoetil)benzoil]-1-(4-fluorofenil)pirazol;
5-amino-1-(4-fluorofenil)-4-[3-(3-morfolin-4-ilpropilamino)benzoil]pirazol;
5-amino-4-[3-(2-aminosulfoniletil)benzoil]-1-(4-fluorofenil)pirazol; i
5-amino-1-(4-fluorofenil)-4-(3-piridin-3-ilbenzoil)pirazol.
92. Spoj prema bilo kojem zahtjevu 1 do 87, naznačen time, da je odabran od:
5-amino-1-(2-metilfenil)-4-[3-piridin-3-il)benzoil]pirazol;
5-amino-1-(2-metilfenil)-4-[3-(N-oksidopiridin-3-il)benzoil]pirazol;
5-amino-4-[3-(2,3-dihidroksipro-poksi)benzoil]-1-(4-fluorofenil)pirazol;
5-amino-4-[3-(1,2-dihidroksietil)benzoil]-1-(4-fluorofenil)pirazol;
5-amino-1-(4-fluorofenil)-4-[3-(sulfamoilbenzoil]pirazol;
5-amino-1-(4-fluorofenil)-4-[3-(3-hidroksi-3-metilbutil)benzoil]pirazol;
5-amino-1-(4-fluorofenil)-4-[3-(2-(1-hidroksiciklopentil)etil)benzoil]pirazol;
5-amino-4-[3-(2-metilsulfoniletil)benzoil]-1-(4-fluorofenil)pirazol; i
5-amino-1-(2,4-difluorofenil)-4-[3-(2-hidroksietilsulfonil)benzoil]pirazol.
93. Spoj prema bilo kojem zahtjevu 1 do 87, naznačen time, da je odabran od:
3-[5-amino-4-(3-jodo-benzoil)-pirazol-1-il]-N-metoksi-4-metil-benzamid;
3-(5-amino-4-benzoil-pirazol-1-il)-N-metoksi-4-metil-benzamid;
3-(5-amino-4-benzoil-pirazol-1-il)-4-metil-benzoična kiselina;
3-(5-amino-4-benzoil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-jodo-benzoil)-pirazol-1-il]-4-metil-benzoična kiselina;
3-[5-amino-4-(3-jodo-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
{5-amino-1-[2-metil-5-(4H-[1,2,4]triazol-3-il)-fenil]-1H-pirazol-4-il}-fenil-metanon;
3-[5-amino-4-(3-[1,3]dioksolan-2-il-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-formil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-hidroksimetil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-{5-amino-4-[3-(4-metil-piperazin-1-ilmetil)-benzoil]-pirazol-1-il}-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-morfolin-4-ilmetil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-morfolin-4-ilmetil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-benziloksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-hidroksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(4-metil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid; i
3-(5-amino-4-benzoil-imidazol-1-il)-N-ciklopropil-4-metil-benzamid.
94. Spoj prema bilo kojem zahtjevu 1 do 87, naznačen time, da je odabran od:
3-{5-amino-4-[3-(2-dimetilamino-etilkarbamoil)-benzoil]-imidazol-1-il}-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(5-kloro-tiofen-2-karbonil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-hidrazinokarbonil-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-(5-amino-4-cikloheksankarbonil-imidazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-(5-mino-4-ciklopentankarbonil-imidazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-(5-amino-4-fenilacetil-imidazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(tetrahidro-piran-4-karbonil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-etilkarbamoil-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid; i
3-[5-amino-4-(3-izopropilkarbamoil-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid.
95. Spoj prema bilo kojem zahtjevu 1 do 87, naznačen time, da je odabran od:
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-3-metil-1H-pirazol-4-karboksilna kiselina etil ester;
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina etil ester;
3-(5-amino-4-ciklopentankarbonil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-hidrazinokarbonil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina benzilamid;
3-(5-amino-4-cikloheksankarbonil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid; i
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina cikloheksilamid.
96. Spoj prema bilo kojem zahtjevu 1 do 87, naznačen time, da je odabran od:
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-3-metilsulfanil-1H-pirazol-4-amid karboksilna kiselina;
5-amino-1-(5-ciklopropilkarbamoil-1-metil-fenil)-3-metansulfonil-1H-pirazol-4-karboksilna kiselina amid;
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-3-metilsulfanil-1H-pirazol-4-karboksilna kiselina etil ester;
5-amino-3-[(3-kloro-benzilkarbamoil)-metoksi]-1-(5-ciklopropilkarbamoil-2-metilfenil)-1H-pirazol-4-karboksilna kiselina etil ester;
3-[5-amino-4-benzoil-3-(piperidin-4-iloksi)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-(5-amino-4-benzoil-3-metansulfonil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-(5-amino-4-benzoil-3-metoksi-pirazol-1-il)-N-ciklopropil-4-metil-benzamid;
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-3-(2-hidroksi-etoksi)-1H-pirazol-4-karboksilna kiselina etil ester;
4-[5-amino-4-benzoil-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-3-iloksi]-piperidin-1-karboksilna kiselina tert-butil ester;
3-(5-amino-4-benzoil-3-metilsulfanil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid; i
3-[5-amino-4-benzoil-3-(2-metoksi-etoksi)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid.
97. Spoj prema bilo kojem zahtjevu 1 do 87, naznačen time, da je odabran od:
3-[5-amino-4-(3-jodo-benzoil)-pirazol-1-il]-N-metoksi-4-metil-benzamid;
3-(5-amino-4-benzoil-pirazol-1-il)-N-metoksi-4-metil-benzamid;
3-(5-amino-4-benzoil-pirazol-1- il)-4-metil-benzoična kiselina;
3-(5-amino-4-benzoil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-jodo-benzoil)-pirazol-1-il]-4-metil-benzoična kiselina;
3-[5-amino-4-(3-jodo-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
{5-amino-1-[2-metil-5-(4H-[1,2,4]triazol-3-il)-fenil]-1H-pirazol-4-il}-fenil-metanon;
3-[5-amino-4-(3-[1,3]dioksolan-2-il-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-formil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-hidroksimetil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-{5-amino-4-[3-(4-metil-piperazin-1-ilmetil)-benzoil]-pirazol-1-il}-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-morfolin-4-ilmetil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-{5-amino-4-[3-(2-morfolin-4-il-etoksi)-benzoil]-pirazol-1-il}-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-benziloksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-hidroksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(4-metil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-(5-amino-4-benzoil-imidazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-(5-amino-4-cikloheksankarbonil-imidazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-(5-amino-4-ciklopentankarbonil-imidazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-(5-amino-4-fenilacetil-imidazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-izopropilkarbamoil-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-{5-amino-4-[3-(2-dimetilamino-etilkarbamoil)-benzoil]-imidazol-1-il}-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-etilkarbamoil-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-metilkarbamoil-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-ciklopropilkarbamoil-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(3-ciklopentilkarbamoil-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-{5-amino-4-[3-(morfolin-4-karbonil)-benzoil]-imidazol-1-il}-N-ciklopropil-4-metil-benzamid;
3-{5-amino-4-[3-(ciklopropilmetil-karbamoil)-benzoil]-imidazol-1-il}-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-(tetrahidro-piran-4-karbonil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-(5-amino-4-benzoil-3-metoksi-pirazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-(5-amino-4-benzoil-3-etoksi-pirazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-benzoil-3-(2-metoksi-etoksi)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
3-[5-amino-4-benzoil-3-(2-benziloksi-etoksi)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid;
4-[5-amino-4-benzoil-1-(5-ciklopropilkarbamoil-2-metil-fenil)-H-pirazol-3-iloksi]-piperidin-1-karboksilna kiselina tert-butil ester;
3-[5-amino-4-benzoil-3-(piperidin-4-iloksi)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid, trifluoracetatna sol;
3-(5-amino-4-benzoil-3-metilsulfanil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid;
3-(5-amino-4-benzoil-3-metansulfonil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid;
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-3-metilsulfanil-1H-pirazol-4-karboksilna kiselina amid;
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-3-metansulfonil-1H-pirazol-4-karboksilna kiselina amid; i
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-3-metilsulfanil-1H-pirazol-4-karboksilna kiselina etil ester.
98. Spoj prema bilo kojem zahtjevu 1 do 87, naznačen time, da je odabran od:
3-[5-amino-4-(3-klorobenzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-metil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid,
3-[5-amino-4-(2-metilbenzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(2-metoksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(4-klorobenzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(2-klorobenzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-metoksi-benzoil)-pirazol-1-il]-4,N-dimetil-benzamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina etil ester,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-3-metil-1H-pirazol-4-karboksilna kiselina etil ester,
5-amino-3-[(3-kloro-benzilkarbamoil)-metoksi]-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina etil ester,
3-(5-amino-4-benzoil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-cijanobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid,
3-[5-amino-4-(3-[1,3,4]oksadiazol-2-il-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-{5-amino-4-[3-(5-metil)-[1,3,4]oksadiazol-2-il)-benzoil]-pirazol-1-il}-N-ciklopropil-4-metil-benzamid,
3-{5-amino-4-[3-(pirolidine-1-karbonil)-benzoil]-imidazol-1-il}-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-ciklopropilkarbamoil-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-karbamoil-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-izopropilkarbamoil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(4-metilkarbamoil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(4-ciklopropilkarbamoil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-karbamoil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-{5-amino-4-[3-(piperazin-1-karbonil)-benzoil]-pirazol-1-il}-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-dimetilkarbamoil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-{5-amino-4-[3-(ciklopropilmetil-karbamoil)-benzoil]-pirazol-1-il}-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-etilkarbamoil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-metilkarbamoil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-ciklopentilkarbamoil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-izopropilkarbamoil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-ciklopropilkarbamoil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-(5-amino-4-{3-[(3-kloro-benzilamino)-metil]-benzoil}-pirazol-1-il)-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-{[2-(3-kloro-fenil)-etilamino]-metil}-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-(5-amino-4-{3-[4-(3-kloro-fenil)-piperazin-1-ilmetil]-benzoil}-pirazol-1-il)-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-{[2-(2-benziloksi-5-kloro-fenil)-etilamino]-metil}-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-(5-amino-4-{3-[(2-morfolin-4-il-etilamino)-metil]-benzoil}-pirazol-1-il)-N-ciklopropil-4-metil-benzamid,
3-(5-amino-4-{3-[(3-morfolin-4-il-propilamino)-metil]-benzoil)-pirazol-1-il)-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(piridin-2-karbonil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(2-metil-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3,4-difluoro-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-fluoro-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3,4-dikloro-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-metoksi-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(4-fluoro-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3,5-dikloro-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(4-metoksi-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-imidazol-4-karbonil]-benzoična kiselina tert-butil ester,
3-[5-amino-4-(3,5-difluoro-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(benzo[1,3]dioksol-5-karbonil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(4-kloro-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3,4-dimetoksi-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-benziloksi-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(4-fluoro-3-metil-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
{3-[5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-imidazol-4-karbonil]-fenoksi}-octena kiselina tert-butil ester,
3-[5-amino-4-(3-kloro-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-(5-amino-4-benzoil-2-metil-imidazol-1-il)-N-ciklopropil-4-metil-benzamid,
3-(5-amino-4-benzoil-2-propil-imidazol-1-il)-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-karbamoilmetoksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-(5-amino-4-{3-[2-(4-metil-piperazin-1-il)-2-okso-etoksi]-benzo}-pirazol-1-il)-N-ciklopropil-4-metil-benzamid,
3- {5-amino-4-[3-(2-okso-2-piperazin-1-il-etoksi)-benzoil]-pirazol-1-il}-N-ciklopropil-4-metil-benzamid,
3-(5-amino-4-{3-[2-(3-amino-pirolidin-1-il)-2-okso-etoksi]-benzoil}-pirazol-1-il)-N-ciklopropil-4-metil-benzamid,
3-(5-amino-4-{3-[2-(3-metilamino-pirolidin-1-il)-2-okso-etoksi]-benzoil}-pirazol-1-il)-N-ciklopropil-4-metil-benzamid,
3-(5-amino-4-{3-[2-(3,5-dimetil-piperazin-1-il)-2-okso-etoksi]-benzoil}-pirazol-1-il)-N-ciklopropil-4-metil-benzamid,
3-(5-amino-4-[3-(2-morfolin-4-il-2-okso-etoksi)-benzoil]-pirazol-1-il}-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-{[(1H-benzoimidazol-2-ilmetil)-karbamoil]-metoksi}-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-{ [2-(2-benziloksi-5-kloro-fenil)-etilkarbamoil]-metoksi}-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-{[2-(5-kloro-2-hidroksi-fenil)-etilkarbamoil]-metoksi}-benzoil)-pirazol-1-il]-N-ciklo-propil-4-metil-benzamid,
3-[5-amino-4-(3-pirazin-2-il-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-piridin-2-il-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(piridin-2-karbonil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-(5-amino-4-ciklopentankarbonil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(benzo[1,3]dioksol-5-karbonil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(2-fluoro-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-etoksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-metoksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-ciklopropoksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(4-metoksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3,4-dimetoksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(4-metilsulfanil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-metilsulfanil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(4-fluoro-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-fluoro-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3,4-difluoro-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3,5-difluoro-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(4-fluoro-3-metil-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(4-fluoro-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-(5-amino-4-cikloheksankarbonil-pirazol-1-il)-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-viniloksi-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-{5-amino-4-[3-([1,3,4]oksadiazol-2-ilmetoksi)-benzoil]-pirazol-1-il}-N-ciklopropil-4-metil-benzamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina (2-metil-cikloheksil)-amid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina fenilamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina (1-etil-propil)-amid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil)-fenil)-1H-pirazol-4-karboksilna kiselina biciklo[2.2.1]hept-2-ilamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina (1-etil)
3-[5-amino-4-(2,5-dimetil-pirolidin-1-karbonil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina 4-metoksi-benzilamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina indan-1-ilamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina benzilamid,
3-[5-amino-4-(piperidin-1-karbonil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina cikloheksilamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina ciklopropilamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina 3-klorobenzilamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina ciklopentilamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina 2,4-dikloro-benzilamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina cikloheksilmetil-amid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina 3,4-dikloro-benzilamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina (4-metil-cikloheksil)-amid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina 3-trifluorometil-benzilamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina (4-tert-butil-cikloheksil)-amid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina (2,2-dimetil-propil)-amid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina 3-metoksi-benzilamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina 4-fluoro-benzilamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina (1-etil-pirolidin-2-il-metil)-amid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina 2-metil-benzilamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina (piridin-2-ilmetil)-amid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina (2-morfolin-4-il-etil)-amid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina (1-cikloheksil-etil)-amid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina (1-fenil-etil)-amid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina (2,2-dimetil-propil)-amid:
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina (1-etil-pirolidin-2-il-metil)-amid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina (2-pirolidin-1-il-etil)-amid,
5-amino-1-(5-ciklopropilkarbamoil-2-metil-fenil)-1H-pirazol-4-karboksilna kiselina cikloheksil-metil-amid,
3-[5-amino-4-(3-cijanobenzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-pirazin-2-il-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-pirimidin-5-il-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-pirimidin-5-il-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-pirimidin-2-il-benzoil)-imidazol-1-il]-N-ciklopropil-4-metil-benzamid,
5-amino-1-(5-ciklopropilkarbamoil-2-metilfenil)-4-metilsulfonilbenzoil-1H-imidazol,
5-amino-1-(5-ciklopropilkarbamoil-2-metilfenil)-4-[3-(5-metil)oksadiazol-3-ilbenzoli]-1H-imidazol,
3-(5-amino-4-{3-[2-(4-metil-piperazin-1-il)-etoksi]-benzoil}-pirazol-1-il)-N-ciklopropil-4-metil-benzamid,
3-[5-amino-4-(3-{2-[bis-(2-hidroksi-etil)-amino]-etoksi)-benzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid,
3-{5-amino-4-[3-(2-dimetilamino-etoksi)-benzoil]-pirazol-1-il}-N-ciklopropil-4-metil-benzamid,
3-{5-amino-4-[3-(2,3-dihidroksi-propoksi)-benzoil]-pirazol-1-il}-N-ciklopropil-4-metil-benzamid,
3-(5-amino-4-{3-[2-(4-kloro-fenoksi)-etoksi]benzoil}-pirazol-1-il)-N-ciklopropil-4-metil-benzamid,
3- {5-amino-4-[3-(4H-[1,2,4]triazol-3-il)-benzoil]-pirazol-1-il}-N-ciklopropil-4-metil-benzamid,
3-{5-amino-4-[3-(4H-[1,2,4]triazol-3-il)-benzoil]-pirazol-1-il}-N-ciklopropil-4-metil-benzamid.
99. Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da:
R1 je vodik ili acil;
R2 je vodik ili alkil;
G ili A je arilni ili heteroarilni prsten;
B je arilni ili heteroarilni prsten;
D je heteroaril, opcijski supstituiran heteroaril ili -C(O)NR80R81 (gdje R80 i R81 su neovisno vodik, alkil, cikloalkil, alkoksi, hidroksi, heteroaril ili opcijski supstituiran heteroaril);
R3 je odabran iz skupine koju čine:
(a) amino, alkilamino ili dialkilamino;
(b) acilamino;
(c) opcijski supstituiran heterociklil;
(d) opcijski supstituiran aril ili heteroaril;
(e) heteroalkil;
(f) heteroalkenil;
(g) heteroalkinil;
(h) heteroalkoksi;
(i) heteroalkilamino;
(j) opcijski supstituiran heterociklilalkil;
(k) opcijski supstituiran heterociklilalkenil;
(l) opcijski supstituiran heterociklilalkinil;
(m) opcijski supstituiran cikloalkoksi, cikloalkilalkiloksi, heterociklilalkoksi ili heterocikliloksi;
(n) opcijski supstituiran heterociklilalkilamino;
(o) opcijski supstituiran heterociklilalkilkarbonil;
(p) heteroalkilkarbonil;
(q) -NHSO2R6 gdje R6 je alkil, heteroalkil ili opcijski supstituiran heterociklilalkil;
(r) -NHSO2NR7R8 gdje R7 i R8 su međusobno neovisno vodik, alkil ili heteroalkil;
(s) -Y-(alkilen)-R9 gdje: Y je jednostruka veza, -O-, -NH- ili -S(O)n (gdje n je cijeli broj od 0 do 2); i R9 je cijano, opcijski supstituiran heteroaril, -COOH, -COR10, -COOR11, -CONR12R13, -SO2R14, -SO2NR15R16, -NHSO2R17ili -NHSO2NR18R19, gdje R10je alkil ili opcijski supstituiran heterocikl, R11 je alkil, a R12, R13, R14, R15 , R16, R17, R18, i R19 su međusobno neovisno vodik, alkil ili heteroalkil;
(v) -C(=NR20)(NR21R22) gdje R20, R21 i R22 neovisno predstavljaju vodik, alkil ili hidroksi, ili su R20 i R21 zajedno -(CH2)n-gdje n je 2 ili 3 i R22 je vodik ili alkil;
(u) -NHC(X)NR23R24 gdje X je -O- ili -S-, i R23 i R24su međusobno neovisno vodik, alkil ili heteroalkil;
(v) -CONR25R26 gdje R25 i R26 neovisno predstavljaju vodik, alkil, heteroalkil ili opcijski supstituiran heterociklilalkil, ili R25 i R26 zajedno s dušikom na koji su priključeni tvore opcijski supstituiran heterociklilni prsten;
(w) -S(O)nR27 gdje n je cijeli broj od 0 do 2, i R27 je alkil, heteroalkil, opcijski supstituiran heterociklilalkil ili -NR28R29gdje R28i R29su međusobno neovisno vodik, alkil ili heteroalkil;
(x) cikloalkilalkil, cikloalkilalkinil i cikloalkilalkinil, svi opcijski supstituirani alkilom, halo, hidroksi ili aminom;
(y) arilaminoalkilen ili heteroarilaminoalkilen;
(z) Z-alkilen-NR30R31 ili Z-alkilen-OR32 gdje Z je -NH-, -N(niži alkil)- ili -O-, i R30, R31 i R32su međusobno neovisno vodik, alkil ili heteroalkil;
(aa) -OC(O)-alkilen-CO2H or -OC(O)-NR’R" (gdje R' i R" su neovisno vodik ili alkil);
i
(bb) heteroarilalkenilen ili heteroarilalkinilen;
R4 je odabran iz skupine koju čine:
(a) vodik;
(b) halo;
(c) alkil;
(d) alkoksi; i
(e) hidroksi;
R5 je odabran iz skupine koju čine:
(a) vodik;
(b) halo;
(c) alkil;
(d) haloalkil;
(e) tioalkil;
(f) hidroksi;
(g) amino;
(h) alkilamino;
(i) dialkilamino;
(j) heteroalkil;
(k) opcijski supstituiran heterocikl;
(l) opcijski supstituiran heterociklilalkil;
(m) opcijski supstituiran heterociklilalkoksi;
(n) alkilsulfonil;
(o) aminosulfonil, mono-alkilaminosulfonil ili dialkilaminosulfonil;
(p) heteroalkoksi; i
(q) karboksi;
R6 je odabran iz skupine koju čine:
(a) vodik;
(b) halo;
(c) alkil; i
(d) alkoksi;
individualni izomeri, smjese izomera i njegovih farmaceutski prihvatljivih soli.
100. Spoj prema bilo kojem zahtjevu 1 do 26, 29 do 61 i 65 do 87, naznačen time, da A ili G je cikloalkilna skupina.
101. Spoj prema bilo kojem zahtjevu 1 do 26, 29 do 61, 65 do 87 i 100, naznačen time, da A ili G je ciklopentilna ili cikloheksilna skupina.
102. Spoj prema bilo kojem zahtjevu 1 do 87, naznačen time, da je to 3-(5-amino-4-benzoil-3-metoksi-pirazol-1-il)-N-ciklopropil-4-metil-benzamid.
103. Spoj prema bilo kojem zahtjevu 1 do 87, naznačen time, da je to 3-[5-amino-4-(3-cijanobenzoil)-pirazol-1-il]-N-ciklopropil-4-metil-benzamid.
104. Farmaceutski sastav, naznačen time, da sadrži spoj prema bilo kojem od zahtjeva 1 do 103 i farmaceutski prihvatljiv nosač.
105. Farmaceutski sastav prema zahtjevu 104, naznačen time, da je formuliran za primjenjivanje u obliku jednostruke doze.
106. Proizvod postupka izrade, naznačen time, da obuhvaća pakirni materijal, spoj prema bilo kojem od zahtjeva 1 do 103, koji je koristan u liječenju, prevenciji ili poboljšanju jednog ili više simptoma bolesti ili poremećaja posredovanih kinazom p38, i etiketu koja naznačava da je spoj koristan za liječenje, prevenciju ili poboljšanje jednog ili više simptoma bolesti ili poremećaja posredovanih kinazom p38.
107. Uporaba spoja prema bilo kojem od zahtjeva 1 do 103, naznačena time, da je za proizvodnju lijeka za liječenje jednog ili više simptoma bolesti ili poremećaja posredovanih kinazom p38.
108. Uporaba prema zahtjevu 107, naznačena time, da je bolest ili poremećaj odabran(a) od upalnih bolesti, autoimunih bolesti, destruktivnih poremećaja koštanog sustava, proliferativnih poremećaja, angiogenih poremećaja, zaraznih bolesti, neurodegenerativnih bolesti i virusnih bolesti.
109. Uporaba prema zahtjevu 107 ili zahtjevu 108, naznačena time, da je bolest ili poremećaj odabran(a) od sljedećih: pankreatitis (akutni ili kronični), astma, alergije, sindrom respiratornog poremećaja kod odraslih, kronična opstrukcijska plućna bolest, glomerulonefritis, reumatoidni artritis, sistemska lupus eritematoza, skleroderma, kronični tiroiditis, Grave-ova bolest, autoimuni gastritis, dijabetes, autoimuna hemolitička anemija, autoimuna neutropenija, trombocitopenija, atopični dermatitis, kronični aktivni hepatitis, miastenija gravis, multipla skleroza, upalna bolest crijeva, ulcerativni kolitis, Crohn-ova bolest, psorijaza, bolesti stanice domaćina kada odbijaju presatke, upalna reakcija izazvana endotoksinom, tuberkuloza, ateroskleroza, mišićna degeneracija, kaheksija, psorijatični artritis, Reiter-ov sindrom, giht, traumatični artritis, rubela artritis, akutni sinovitis, bolest β-stanice gušterače;
bolesti karakterizirane masivnom infiltracijom neutrofila;
reumatoidni spondilitis, kostobolni artritis i ostala artritična stanja, cerebralna malarija, kronična upala pluća, silikoza, plućna sarkoidoza, bolest resorpcije koštanog sustava, odbijanje presadaka, groznica i mialgija zbog infekcije, kaheksija kao posljedica infekcije, meloidne formacije, stvaranje rana u tkivu, ulcerativni kolitis, pireza, influenca, osteoporoza, osteoartritis i poremećaj koštanog sustava uslijed multiplog mijeloma, akutna mijelogena leukemija, kronična mijelogena leukemija, metastatični melanom, Kaposi-jev sarkom, multipli mijelom, sepsa, septički šok, i Shigelloza;
Alzheimer-ova bolest, Parkinson-ova bolest, cerebralne ishemije ili neurodegenerativna bolest uzrokovana traumatičnom ozljedom; angiogenični poremećaji uključujući čvrste tumore, očna neovaskulizacija, i infantilni hemangiomi; virusne bolesti uključujući infekciju kod akutnog hepatitisa (uključujući hepatitis A, hepatitis B i hepatitis C), HIV infekciju i CMV retinitis, AIDS, SARS, ARC ili maligne bolesti i herpes; moždani udar, miokardijska ishemija, ishemija kod srčanog udara, organohipozija, vaskularna hiperplazija, kardijska i renalna reperfuzijska ozljeda, tromboza, kardijska hipertrofija, agregacija trombocita izazvana trombom, endotoksemija i/ili sindrom toksičnog šoka, te stanja povezana sa sintezom-2 prostaglandinske endoperoksidaze.
110. Farmaceutski sastav prema zahtjevu 104 ili zahtjevu 105, naznačen time, da nadalje sadrži jedan ili više od sljedećih tvari: kortikosteroid, rolipram, kalfostin, CSAID, 4-supstituiran imidazo[1,2-A]kinoksalin, interleukin-10, aglukokortikoid, salicilat, dušikov oksid, imunosupresant, inhibitor nuklearne translokacije, deoksispergualin (DSG); ne-steroidni protuupalni lijek (NSAID), ibuprofen, celekoksib, rofekoksib; steroid, prednizon, deksametazon;
protuvirusno sredstvo, abakavir; protuproliferativno sredstvo, metotreksat, leflunomid, FK506;
citotoksični lijek, azatioprin, ciklofosfamid, inhibitor TNF-α, tenidap, ananti-TNF protutijelo, topljivi receptor TNF, irapamicin, ili njihovi derivati.
111. Uporaba prema zahtjevu 107, naznačena time, da kinaza je p38α kinaza ili p38β kinaza.
112. Postupak priprave spoja prema zahtjevu 16, naznačen time, da obuhvaća korake (i) i (iii) do (vi), ili korake (ii) do (vi), kako slijedi:
(i) reagiranje 2-keto-3-fenilaminoakrilonitrila formule 1:
[image]
s hidrazinom formule 2:
[image]
za dobivanje spoja formule (I) gdje R1 je vodik; ili
(ii) reagiranje 2-keto-3-fenilaminoakrilonitrila formule 3:
[image]
gdje Z je hidroksi, nitro ili halo, s hidrazinom formule 2 za dobivanje spoja formule 4:
[image]
zatim slijedi pretvaranje Z skupine u željenu skupinu R3 za dobivanje spoja prema zahtjevu 1 gdje R1 je vodik;
(iii) opcijski modificiranje bilo koje skupine od R1, R3, R4, R5 ili R6;
(iv) opcijski pretvaranje spoja formule (I) pripravljenog u gornjim koracima (i), (ii) ili (iii), u odgovarajuću adicijsku kiselinsku sol pomoću tretiranja s kiselinom;
(v) opcijski pretvaranje spoja formule (I) pripravljenog u gornjim koracima (i), (ii) ili (iii), u odgovarajuću slobodnu bazu pomoću tretiranja s bazom; i
(vi) opcijski odvajanje smjese stereoizomera od spoja formule (I) pripravljenog u gornjim koracima (i) do (v), za stvaranje jednostrukog stereoizomera.
113. Postupak priprave spoja prema zahtjevu 16, naznačen time, da postupak uključuje reagiranje spoja formule 5:
[image]
gdje L je izlazna skupina pod uvjetima reakcije organometalnog istiskivanja, s organometalnim reagensom formule:
[image]
gdje M je metalna polovica, za dobivanje spoja formule (I) gdje R1 je vodik;
(ii) opcijski modificiranje bilo koje od skupina R1, R3, R4, R5 ili R6;
(iii) opcijski pretvaranje spoja formule (I) pripravljene u gornjim koracima (i) ili (ii), u odgovarajuću adicijsku kiselinsku sol pomoću tretiranja s kiselinom;
(iv) opcijski pretvaranje spoja formule (I) pripravljene u gornjim koracima (i) ili (ii), u odgovarajuću slobodnu bazu pomoću tretiranja s bazom; i
(v) opcijski odvajanje smjese stereoizomera od spoja pripravljenog u gornjim koracima (i) ili (iv), da se dobije jednostruki stereoizomer.
114. Spoj prema bilo kojem od zahtjeva 1 do 103, naznačen time, da služi za liječenje, prevenciju ili poboljšanje jednog ili više simptoma bolesti ili poremećaja posredovanih p38 kinazom.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48342803P | 2003-06-26 | 2003-06-26 | |
US49905403P | 2003-08-29 | 2003-08-29 | |
US56048104P | 2004-04-07 | 2004-04-07 | |
PCT/US2004/020384 WO2005009973A1 (en) | 2003-06-26 | 2004-06-24 | 5-membered heterocycle-based p38 kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110757T1 true HRP20110757T1 (hr) | 2011-11-30 |
Family
ID=34108816
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110757T HRP20110757T1 (hr) | 2003-06-26 | 2011-10-18 | Inhibitori kinaze p38 bazirani na 5-članom heterociklu |
HRP20120900TT HRP20120900T1 (hr) | 2003-06-26 | 2012-11-08 | Inhibitori p38 kinaze bazirani na peteroäślanom heterociklu |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120900TT HRP20120900T1 (hr) | 2003-06-26 | 2012-11-08 | Inhibitori p38 kinaze bazirani na peteroäślanom heterociklu |
Country Status (27)
Country | Link |
---|---|
US (4) | US7863314B2 (hr) |
EP (2) | EP2298743B1 (hr) |
JP (1) | JP4838121B2 (hr) |
KR (1) | KR101120857B1 (hr) |
CN (1) | CN1832928B (hr) |
AT (1) | ATE517872T1 (hr) |
AU (1) | AU2004259662B2 (hr) |
BR (1) | BRPI0411825B8 (hr) |
CA (1) | CA2526455C (hr) |
CY (2) | CY1111985T1 (hr) |
DK (2) | DK2298743T3 (hr) |
EC (2) | ECSP056206A (hr) |
ES (1) | ES2393950T3 (hr) |
HK (2) | HK1088895A1 (hr) |
HR (2) | HRP20110757T1 (hr) |
IL (1) | IL172182A (hr) |
IS (2) | IS2916B (hr) |
MA (1) | MA27888A1 (hr) |
MX (1) | MXPA05013824A (hr) |
MY (1) | MY158162A (hr) |
NO (1) | NO334947B1 (hr) |
NZ (1) | NZ544230A (hr) |
PL (2) | PL1641764T3 (hr) |
PT (2) | PT1641764E (hr) |
SI (2) | SI1641764T1 (hr) |
TW (2) | TWI452035B (hr) |
WO (1) | WO2005009973A1 (hr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7485657B2 (en) | 2004-05-12 | 2009-02-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
CA2606226A1 (en) * | 2005-04-27 | 2006-11-02 | University Of Florida Research Foundation, Inc. | Materials and methods for enhanced degradation of mutant proteins associated with human disease |
DE102005031580A1 (de) * | 2005-07-06 | 2007-01-11 | Aicuris Gmbh & Co. Kg | Substituierte Sulfolanylpyrazole und ihre Verwendung |
GB0603684D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
KR20110007258A (ko) | 2006-03-22 | 2011-01-21 | 에프. 호프만-라 로슈 아게 | 11-베타-hsd-1로서의 피라졸 |
CA2648407A1 (en) * | 2006-04-03 | 2007-10-18 | Stowers Institute For Medical Research | Compositions and methods for treating polycystic kidney disease |
BRPI0717873A2 (pt) * | 2006-10-30 | 2013-10-29 | Novartis Ag | Derivado de 3-amino-pirazol-4-carboxamida úteis como inibidores de proteína quinases |
GB0621978D0 (en) * | 2006-11-03 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of p38 mitogen-activated protein kinase |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
WO2009011897A1 (en) * | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Combinations for the treatment of b-cell proliferative disorders |
CA2694983A1 (en) * | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Treatments of b-cell proliferative disorders |
AU2008275891B2 (en) * | 2007-07-19 | 2013-10-10 | H.Lundbeck A/S | 5-membered heterocyclic amides and related compounds |
WO2009085797A1 (en) * | 2007-12-21 | 2009-07-09 | Gilead Sciences, Inc. | Processes for preparing hiv reverse transcriptase inhibitors |
DE102008015033A1 (de) * | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
US20090281150A1 (en) * | 2008-04-09 | 2009-11-12 | Nicola Frances Bateman | Compound 249 |
WO2009151569A2 (en) * | 2008-06-09 | 2009-12-17 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
JP5600104B2 (ja) | 2008-08-01 | 2014-10-01 | ベンティアールエックス ファーマシューティカルズ, インコーポレイテッド | Toll様受容体アゴニスト処方物およびその使用 |
ES2705101T3 (es) | 2008-11-06 | 2019-03-21 | Ventirx Pharmaceuticals Inc | Métodos de síntesis de derivados de benzazepinas |
BR112012008094A2 (pt) | 2009-08-07 | 2020-08-18 | Chugai Seiyaku Kabushiki Kaisha | derivado de aminopirazol, seu uso, composição farmacêutica que o compreende, agentes para inibir a atividade de fgfr e para prevenir ou tratar câncer |
EP2467380B1 (en) | 2009-08-18 | 2016-11-30 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
CN105669553A (zh) | 2009-08-18 | 2016-06-15 | 文蒂雷克斯药品公司 | 作为toll样受体调节剂的取代的苯并氮杂* |
WO2011038261A1 (en) * | 2009-09-24 | 2011-03-31 | Selexagen Therapeutics, Inc. | Heterocyclic kinase inhibitors |
CA2789847A1 (en) | 2010-02-15 | 2011-08-18 | Synovo Gmbh | Kinase modulators for the treatment of cancer |
EP3061751A1 (en) * | 2010-09-21 | 2016-08-31 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
US8993631B2 (en) | 2010-11-16 | 2015-03-31 | Novartis Ag | Method of treating contrast-induced nephropathy |
EP2460519A1 (en) * | 2010-12-03 | 2012-06-06 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in bone cancer pain |
JP5620417B2 (ja) * | 2011-02-07 | 2014-11-05 | 中外製薬株式会社 | アミノピラゾール誘導体を含む医薬 |
NZ628392A (en) * | 2012-03-20 | 2016-06-24 | Mereo Biopharma 1 Ltd | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease |
WO2015084936A1 (en) * | 2013-12-04 | 2015-06-11 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
US9802920B2 (en) | 2013-12-13 | 2017-10-31 | Hoffman-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
CN105814035B (zh) | 2013-12-13 | 2018-02-02 | 豪夫迈·罗氏有限公司 | 布鲁顿氏酪氨酸激酶抑制剂 |
WO2015099127A1 (ja) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬 |
US10479780B2 (en) | 2015-06-17 | 2019-11-19 | Chugai Seiyaku Kabushiki Kaisha | Aminopyrazole derivatives |
US10214515B2 (en) * | 2015-08-20 | 2019-02-26 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Substituted pyrazoles as inhibitors of fibroblast growth factor receptor |
CA3016488C (en) | 2016-03-08 | 2023-04-11 | Mereo Biopharma 1 Limited | Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease |
WO2017153701A1 (en) | 2016-03-08 | 2017-09-14 | Mereo Biopharma 1 Limited | Dosage regimen for the treatment of acute exacerbations of inflammatory conditions |
GB201612240D0 (en) * | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
GB201612238D0 (en) * | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide |
WO2018059533A1 (zh) * | 2016-09-29 | 2018-04-05 | 南京明德新药研发股份有限公司 | p38αMAPK激酶抑制剂及其制备方法和应用 |
WO2018109667A1 (en) | 2016-12-15 | 2018-06-21 | Nestec Sa | Compositions and methods that modulate white blood cells or neutrophils in a companion animal |
CA3128468A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
HUE054266T2 (hu) | 2017-12-11 | 2021-08-30 | Mereo Biopharma 1 Ltd | 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus obstruktív tüdõbetegség akut megjelenésének megelõzésében |
EP3585382B1 (en) | 2017-12-11 | 2021-07-14 | Mereo BioPharma 1 Limited | Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease |
JP2021519334A (ja) | 2018-03-26 | 2021-08-10 | クリア クリーク バイオ, インコーポレイテッド | ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法 |
EP3563848A1 (en) * | 2018-04-30 | 2019-11-06 | S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati | Serpin inhibitors for the treatment of prion and prion-like diseases |
GB201815696D0 (en) * | 2018-09-26 | 2018-11-07 | Mereo Biopharma 1 Ltd | Synthetic method |
GB201815699D0 (en) * | 2018-09-26 | 2018-11-07 | Mereo Biopharma 1 Ltd | Synthetic method |
GB201815695D0 (en) * | 2018-09-26 | 2018-11-07 | Mereo Biopharma 1 Ltd | Synthetic method |
CN110950848B (zh) * | 2018-09-27 | 2024-03-26 | 徐诺药业 | 新型氨基吡唑类衍生物的合成与应用 |
CN113015730A (zh) * | 2018-11-13 | 2021-06-22 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
CN112778333B (zh) * | 2021-01-23 | 2022-07-05 | 中国科学院新疆理化技术研究所 | 一种四氢噁唑并吡啶并氮氧杂酮类衍生物及其用途 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1152421B (de) | 1961-03-21 | 1963-08-08 | Bayer Ag | Verfahren zur Herstellung von 4-Hydroxy-pyrazolo[3, 4-b]chinolinen |
JPS5111499Y2 (hr) | 1971-04-22 | 1976-03-27 | ||
USRE28819E (en) * | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
JPS5527916B2 (hr) | 1973-02-05 | 1980-07-24 | ||
JPS51112341A (en) | 1975-02-24 | 1976-10-04 | Konishiroku Photo Ind Co Ltd | Magenta dye image formation |
US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
US6005109A (en) * | 1997-10-30 | 1999-12-21 | Pflizer Inc. | Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity |
US6103900A (en) * | 1992-12-17 | 2000-08-15 | Pfizer Inc | Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity |
DE69323212T2 (de) | 1992-12-17 | 1999-05-27 | Pfizer | Pyrazole mit crf antagonistischer aktivität |
US5514643A (en) | 1993-08-16 | 1996-05-07 | Lucky Ltd. | 2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms |
US5646152A (en) | 1994-06-15 | 1997-07-08 | Pfizer Inc. | Methods of administering CRF antagonists |
CA2163399A1 (en) | 1994-11-24 | 1996-05-25 | Katsuhiro Kawano | Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor |
DE19518054A1 (de) | 1995-03-08 | 1996-09-12 | Hoechst Schering Agrevo Gmbh | N-Arylpyrazolketone und deren Derivate, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel |
US5658903A (en) | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
NZ327044A (en) | 1996-01-11 | 2000-01-28 | Smithkline Beecham Corp | Substituted imidazole compounds |
US5945418A (en) | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
WO1998028269A1 (en) | 1996-12-23 | 1998-07-02 | Du Pont Pharmaceuticals Company | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS |
WO1998052937A2 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase |
US6087496A (en) | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
WO1999001452A1 (en) | 1997-07-02 | 1999-01-14 | Smithkline Beecham Corporation | Novel cycloalkyl substituted imidazoles |
YU22400A (sh) | 1997-10-27 | 2003-08-29 | Agouron Pharmaceuticals Inc. | Supstituisana 4-amino-tiazol-2-i jedinjenja kao cdks inhibitori |
US6376527B1 (en) | 1998-05-05 | 2002-04-23 | Syntex (U.S.A.) Llc | Pyrazole derivatives-p38 map kinase inhibitors |
US20020156114A1 (en) | 1998-05-05 | 2002-10-24 | Goldstein David Michael | Pyrazole derivatives - p38 MAP kinase inhibitors |
US6316466B1 (en) | 1998-05-05 | 2001-11-13 | Syntex (U.S.A.) Llc | Pyrazole derivatives P-38 MAP kinase inhibitors |
NZ507558A (en) | 1998-05-05 | 2003-08-29 | F | Pyrazole derivatives as P-38 map kinase inhibitors |
US6130235A (en) | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
AU772477B2 (en) | 1998-08-28 | 2004-04-29 | Scios Inc. | Inhibitors of p38-alpha kinase |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
WO2000025780A1 (en) | 1998-10-29 | 2000-05-11 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
BR0009721A (pt) | 1999-04-15 | 2002-02-13 | Bristol Myers Squibb Co | Inibidores de tirosina quinase de proteìna cìclica |
GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
NZ512957A (en) | 1999-11-10 | 2005-01-28 | Ortho Mcneil Pharm Inc | Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a] pyrimidines and their use in inhibiting in vitro secretion of TNF-alpha and IL-1beta to treat neurodegenerative diseases |
AU2001230026A1 (en) | 2000-02-04 | 2001-08-14 | Novo-Nordisk A/S | 2,4-diaminothiazole derivatives |
AU9625501A (en) | 2000-09-21 | 2002-04-02 | Bristol Myers Squibb Co | Substituted azole derivatives as inhibitors of corticotropin releasing factor |
CA2429628A1 (en) | 2000-11-17 | 2002-05-23 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
AU2002219678A1 (en) | 2001-01-17 | 2002-07-30 | Boyean Kim | Sun visor having office work apparatus |
US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
MXPA03010269A (es) | 2001-05-11 | 2004-05-05 | Vertex Pharma | Derivados de 2,5-disubstituida piridina, pirimidina, piridazina y 1,2,4-triazina para usarse como inhibidores de p38. |
HN2002000156A (es) | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
GB0124936D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124939D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124932D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124931D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124928D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124938D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124933D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124934D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
PT1699800E (pt) * | 2003-12-23 | 2010-04-12 | Novartis Ag | Inibidores de quinase p-38 heterocíclicos bicíclicos |
JP2007084437A (ja) | 2003-12-26 | 2007-04-05 | Dai Ichi Seiyaku Co Ltd | アミノアルキルピラゾール誘導体 |
-
2004
- 2004-06-24 TW TW093118259A patent/TWI452035B/zh not_active IP Right Cessation
- 2004-06-24 DK DK10164367.4T patent/DK2298743T3/da active
- 2004-06-24 MX MXPA05013824A patent/MXPA05013824A/es active IP Right Grant
- 2004-06-24 PT PT04777075T patent/PT1641764E/pt unknown
- 2004-06-24 PL PL04777075T patent/PL1641764T3/pl unknown
- 2004-06-24 CN CN2004800180564A patent/CN1832928B/zh active Active
- 2004-06-24 PL PL10164367T patent/PL2298743T3/pl unknown
- 2004-06-24 SI SI200431766T patent/SI1641764T1/sl unknown
- 2004-06-24 WO PCT/US2004/020384 patent/WO2005009973A1/en active Application Filing
- 2004-06-24 DK DK04777075.5T patent/DK1641764T3/da active
- 2004-06-24 EP EP10164367A patent/EP2298743B1/en active Active
- 2004-06-24 AU AU2004259662A patent/AU2004259662B2/en active Active
- 2004-06-24 JP JP2006517650A patent/JP4838121B2/ja active Active
- 2004-06-24 BR BRPI0411825A patent/BRPI0411825B8/pt not_active IP Right Cessation
- 2004-06-24 KR KR1020057024679A patent/KR101120857B1/ko active IP Right Grant
- 2004-06-24 AT AT04777075T patent/ATE517872T1/de active
- 2004-06-24 NZ NZ544230A patent/NZ544230A/en unknown
- 2004-06-24 CA CA2526455A patent/CA2526455C/en active Active
- 2004-06-24 ES ES10164367T patent/ES2393950T3/es active Active
- 2004-06-24 SI SI200431950T patent/SI2298743T1/sl unknown
- 2004-06-24 PT PT101643674T patent/PT2298743E/pt unknown
- 2004-06-24 EP EP04777075A patent/EP1641764B1/en active Active
- 2004-06-24 TW TW100114024A patent/TWI449696B/zh not_active IP Right Cessation
- 2004-06-25 MY MYPI20042496A patent/MY158162A/en unknown
- 2004-06-25 US US10/877,534 patent/US7863314B2/en active Active
-
2005
- 2005-11-24 IL IL172182A patent/IL172182A/en active IP Right Grant
- 2005-12-08 EC EC2005006206A patent/ECSP056206A/es unknown
- 2005-12-21 MA MA28678A patent/MA27888A1/fr unknown
-
2006
- 2006-01-23 IS IS8255A patent/IS2916B/is unknown
- 2006-01-26 NO NO20060424A patent/NO334947B1/no unknown
- 2006-08-16 HK HK06109122.6A patent/HK1088895A1/xx unknown
- 2006-08-16 HK HK11107635.3A patent/HK1149764A1/xx not_active IP Right Cessation
-
2010
- 2010-11-19 US US12/950,649 patent/US8242117B2/en active Active
-
2011
- 2011-10-18 HR HR20110757T patent/HRP20110757T1/hr unknown
- 2011-10-27 CY CY20111101022T patent/CY1111985T1/el unknown
-
2012
- 2012-02-07 EC ECSP12006206 patent/ECSP12006206A/es unknown
- 2012-06-22 US US13/530,919 patent/US8410160B2/en active Active
- 2012-11-08 CY CY20121101064T patent/CY1113313T1/el unknown
- 2012-11-08 HR HRP20120900TT patent/HRP20120900T1/hr unknown
-
2013
- 2013-02-25 US US13/775,963 patent/US8580838B2/en active Active
-
2014
- 2014-01-28 IS IS9037A patent/IS2984B/is unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110757T1 (hr) | Inhibitori kinaze p38 bazirani na 5-članom heterociklu | |
KR100488610B1 (ko) | 카나비노이드수용체친화력을지닌3-피라졸카르복사미드유도체 | |
JP4693787B2 (ja) | Cb1拮抗活性を有する1,3,5−三置換4,5−ジヒドロ−1h−ピラゾール誘導体 | |
DE69836422T2 (de) | N-heterocyclische derivate als nos inhibitoren | |
AU2007305235C1 (en) | Pyrazole derivatives as modulators of the 5-HT2a serotonin receptor useful for the treatment of disorders related thereto | |
US20020165203A1 (en) | N-heterocyclic derivatives as NOS inhibitors | |
DE60020560T2 (de) | Substituierte pyrazol-derivate | |
JP2010526793A (ja) | P2x7調節因子としてのピラゾール誘導体 | |
CA2650622A1 (en) | Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists | |
AU2006271499A1 (en) | Pyrazole derivatives as CB1 modulators | |
AU2005271162A1 (en) | Mercaptoimidazoles as CCR2 receptor antagonists | |
US20070281974A1 (en) | 1 h-imidazole derivatives as cannabinoid receptor modulators | |
ES2369541T3 (es) | Inhibidores de quinasa p38 basados en heterociclos de 5 miembros. | |
US20100292204A1 (en) | Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists | |
RU2006102023A (ru) | Производные 5-членных гетероциклов в качестве ингибиторов киназы p38 | |
MX2008015272A (es) | Derivados de pirazol que contienen azufre como antagonistas selectivos del receptor cannabinoide cb1. |